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Spinal muscular atrophy (SMA) is a common autosomal recessive disorder and the leading
cause of infant mortality. Patients with this disorder are missing the SMN1 gene that is
producing 80-90 % of the Spinal motor neuron (SMN) protein. The SMN2 gene is not
able to produce the full-length protein, due to a small difference in the splicing pattern.
This leads to loss of muscle function and physical disability.
Different treatments ave been performed on patients with SMA, and one of them is to
increase the SNM2 gene. In 2012 Androphy et al ., in collaboration with Dr. Hodgetts at
the LDDN, discovered two hit compounds that increase the SMN protein. Based on one
of these compounds, the research group at LDDN optimized the molecule and produced
a better probe for the treatment of SMA. In this project, the synthesized probe will be
optimized by changing the heterocycle, with the same substituents and amide linker.
Different synthesis has been performed, before reaching the target molecule. Amidation
with acid chloride and an amine is the main reaction leading to the target molecule. In
addition to the target molecule, different analogs have also been made. The substituents
on the heterocycle and the amide linker have been modified, leading to several new
compounds.
All of the compounds that were synthesized, were also sent for testing at the Department
of Dermatology, Indiana University School of Medicine. The main reason for the testing
is to see if the compounds are active or not in the treatment for SMA. The % activation
and the EC50 value for each compound in mouse models were determined. Based on the
previously synthesized molecule, the target molecule was expected to be active. This
turned out to be wrong, and the target molecule was inactive. However, one of the other
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1 Introduction
1.1 Spinal muscular atrophy (SMA)
Spinal muscular atrophy (SMA) is an autosomal recessive neurodegenerative disorder
characterized by muscle weakness and eventual loss of motor function [1]. This disorder
can occur in different forms and is caused by low levels of the Survival motor neuron
(SMN) protein. The presence of this disease is most common in infancy or childhood,
but can also be onset in adulthood and leading to different levels of physical disability
[2].
Telomeric SMN1 and centromeric SMN2 are two nearly identical SMN genes that are
found on chromosome 5q11-13 and produce the SMN protein that is important for the
function of the nerves that control the muscles [3]. The normal population typically have
two copies of the SMN1 gene and up to four copies of the SMN2 gene. SMA carriers
are missing the two SMN1 copies or have a mutation in the gene. The mutation causes
a sequence difference between the two genes and leads to a skipping of exon 7 during
transcription. This results in the SMN2 gene producing a truncated, non-functional, and
rapidly degrading unstable protein. A change in this gene causes reduced levels of the
SMN protein and loss of muscle function.
The SMN1 gene is the main source of the SMN protein, and is responsible for producing
80-90 % of the protein, while SMN2 is responsible for 10-20 %, due to a small difference in
the splicing pattern that makes it less functional [4]. Copies of SMN2 alone will therefore
be unable to express the full-length protein and produce an unstable protein that will
not generate full function of motor neurons [2]. Figure 1.1 shows the encode of the SMN
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Figure 1.1: Encode of SMN protein, where you see the difference between the two SMN genes [6]
Based on the level of muscle function and the age of onset, SMA has been classified into
four types [5]. The most severe form of SMA is called Type I and is one of the leading
causes of infant mortality. Infants with this type will show muscle weakness within 6
months, and death often occurs within 2 years due to respiratory failure [3]. Type I
patients only possess 2-3 copies of the SMN2 gene, while patients with Type II, possess
3-4 copies, and will show muscle weakness in early childhood. Type III and IV are in
general a milder form of SMA and will not affect the patients before later adulthood, due
to more copies of SMN2 [6].
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There is no genetic way to cure SMA, but there are different treatments that have been
performed on individuals. Physical treatments such as respiratory support, has been used
to extend the life of a patient. It does not slow down the progression of the disease, but
it can improve the quality of the life [4]. Since these types of methods do not stop or
slow down the progression of SMA, different research groups are exploring methods to
produce small molecules that can treat affected individuals. Spinraza is one example of a
drug that increases the length of the SMN protein [7], but there is clearly need for more
drug candidates.
1.2 Previous work
From the different treatments that have been performed on patients with SMA, therapeu-
tic treatment focuses on the increase of the full-length protein. An increase in the SNM2
gene will increase the full-length protein [5]. This has been confirmed in mouse models,
by introducing two copies of human SMN2 genes to the mouse [8]. Even if the amount of
SMN2 copies is a high-priority target for the increase of the full-length protein, there are
other options. Some of these methods involve SMN1 gene replacement and motor neuron
replacement with stem cell therapy [5]. Another option is to produce small molecules and
compounds that post-transitionally stabilizes the SMN protein.
In 2012 Androphy et al . [9, 10] in collaboration with the LDDN, published an article
where they discovered two hit compounds from a large screening of over 150,000 com-
pounds. The two hit compounds had the best activity and increased the SMN protein.
Figure 1.2 shows some of the different analogs that have been tested. Compound LDN-




































Figure 1.2: Different analoges synthesized and tested by Jonathan J. Cherry et al . [9]
Dr. Hodgetts and the research group at LDDN continued the optimization of LDN-
75654. Figure 1.3 shows that LDN-75654 has been optimized to a small molecule
probe that has been synthesized (LDN-27). The amide bond was reversed and the
heterocycle was changed to achieve this compound. This compound post-transnationally
stabilizes the SNM protein and will increase the levels of the full-length SMN protein.
Figure 1.3: Hit compound and the optimized probe synthesized by Dr. Hodgetts et al . [3]
Figure 1.4 shows the % activation graphs for LDN-75654 and LDN-27. This shows
that both of the compounds are active and good options to increase the SMN protein for
treatment of SMA.
Figure 1.4: % activation graphs for LDN-75654 and LDN-27
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The optimization was based on a structure-activity relationship (SAR) study, where dif-
ferent analogs were synthesized and tested. Various substituents at the heterocycle have
been tried, in addition to different groups attached to the carbonyl in the amide. An im-
portant functional group that was required for the activity was the amide linker. Several
different heterocycles have been tried, with different substituents (Figure 1.5). Based on
the result and the activity of the compounds, LDN-27 (Figure 1.3) was the probe that
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Figure 1.5: Different analogs from SAR study
Even though this compound showed good results in a mouse model of SMA, it will still
need additional optimization to be used as a drug for SMA. Further optimization and
new analogs were synthesized and tested in this project.
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1.3 Aim of study
The aim of this project was to develop and synthesize analogs of the previously synthe-
sized molecule (LDN-27) at LDDN (Figure 1.3, page 4). The goal was to develop new
derivatives that will be tested for activity in the stabilization of SMN protein, for the
treatment of SMA.
The new approach was to change the thiazol to a new heterocycle. Isoxazole and thia-
zole have been tried, but never imidazoles. The new analogs have an imidazole as the
heterocycle and different substituents, both at the backbone and at the nitrogen in the
imidazole, have been tried and synthesized. The goal was to optimize the molecule and
create different analogs for testing. The molecule synthesized at LDDN (LDN-27), was
















Figure 1.6: Previously syntesized molecule (LDN-27) and target molecule (A)
Imidazole and derivatives are important substances that are included in both biological
and medicinal chemistry and can be a good approach for the new analogs. The imidazole
ring and derivatives are found in several compounds that show biological activity and are
of pharmaceutical importance [11]. Based on this, analogs with imidazole as the center
of the compound may show activity in the stabilization of the SMN protein.
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2 Theory of instrumentation
2.1 Nuclear magnetic resonance
Nuclear magnetic resonance (NMR) has been used as an analytical instrument for many
years and is today an important technique for both chemists, biochemists and physicists
[12]. NMR is based on the nuclear magnetic field in the instrument. Radiofrequency
waves are used to get information about the different magnetic and chemical environment
around the NMR active nucleus [13]. This is used to find the composition and molecular
structure of a component. 1H and 13C are the most common NMR active nuclei that are
analyzed and relevant for this project [14].
Figure 2.1 shows a schematic diagram of a NMR spectrophotometer and how it operates.
The sample is placed in a tube between the poles of a magnet and irradiated with ra-
diofrequency waves from the generator. For all of the nuclei to come into resonance in
different field strength, the frequency of the radiation is constant and the applied mag-
netic field is varied. A detector monitors the absorption of radiofrequency energy, and
the signals are amplified and displayed as a peak in the NMR spectrum [15].
Figure 2.1: Shematic operation of a basic NMR spectrometer [15]
To record an NMR spectrum the nuclei in the molecule that is analyzed needs to have
a spin. This is created when a positively charged nucleus, moves from one spin state to
another due to the radiofrequency waves. This can only happen when a magnetic field
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is applied, and the nucleus interacts with this field [13]. This means that the spherical
nucleus rotates around their own axis and produce a nuclear spin.
If a nucleus is placed in a static magnetic field, Bo, a nuclear spin will be produced. This
creates different energy levels, depending on the different number of spins each nucleus
have. Transitions between these levels can be induced by irradiating the nucleus with
electromagnetic waves of the appropriate frequency, which corresponds with the difference
in energy levels [16]. The transition between two levels corresponds to the absorption of
energy. Absorption occurs between the transition from the lower level to the higher level,
and the nucleus will be in resonance with the applied radiation [15].
All 1H and 13C nuclei in a molecule do not absorb energy at the same frequency. This
leads to a different NMR spectrum for each molecule, which is why NMR analyzes is so
useful. Electrons surround the nucleus in all molecules, and these electrons will move
around when the magnetic field is applied. The electrons make their own local magnetic
field and make the nucleus shielded by the external field. Each nucleus in a molecule
is surrounded by different electronic environments, and will therefore be shielded to a
different extent. The difference between the applied magnetic field and the local magnetic
field can be detected. The detected absorption can be amplified and displayed as an NMR
spectrum [15].
For each 1H and 13C nucleus in a molecule, there is a distinct NMR signal, based on the
unique absorption. The exact position of each signal is called a chemical shift. Based
on the electronic environment, different 1H and 13C nuclei have different chemical shifts.
Nuclei that are more shielded from surrounding electrons require higher field strength
for resonance and will absorb in the upfield part of the NMR spectrum. For nuclei that
are less shielded, the required field strength for resonance is lower and will absorb in the
downfield part of the NMR spectrum [15].
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2.2 Masspectroscopy
Mass spectroscopy (MS) is a powerful technique to determine the molecular weight of a
compound. In some instruments, it is possible to measure the mass of the fragments pro-
duced when molecules are broken apart through the system. The mass of the fragments
can then be used to determine the exact structure of a molecule.
Figure 2.2: Shematic operation of a basic mass spectrometer [17]
The most common mass spectrometers consist of an ionization source, a mass analyzer
and a detector. In addition to this, there is a sample inlet and a data system that display
the mass spectrum. Figure 2.2 shows the schematic operation of a mass spectrometer.
The most used ionization sources are Electron Impact (EI), Electrospray Ionization (ESI)
and Matrix-Assisted Laser Desorption Ionization (MALDI). The main function of the
ionization source is to bombard the sample with high-energy electrons, which ionizes the
molecule and creates different fragments. The fragments will then be extracted into the
mass analyzer and separated according to their mass to charge ratio (m/z). The most
common mass analyzer are magnetic sector, Time-of-flight (TOF) and Quadrupole (Q).
A detector will then detect the separated ions, and the signals are sent to a data system,
where the m/z ratios are stored together with their relative abundance. Based on the m/z
ratios the ions produce different peaks with different relative abundances. The number
of charge on each ion is normally 1, which means that the value of m/z for each ion
represents the mass of the molecule or fragment [15].
In some instances where you only need the mass of a compound, ESI as the ionization
source is most common. Mostly one ion of each molecule in a sample is produced, which is
very useful in synthesis, where you often have other compounds than the desired product.
This can then be used to determine the composition of your sample.
9
2.3 Microwave
The use of microwave heating in chemistry is an increasingly more common approach to
drive a chemical reaction. The main reason for this is that the rapid and appropriate
heat increases the rate of the reaction significantly [18]. Another advantage of microwave
heating is that the reaction time is reduced. Reactions that take days can be carried out
in just a few hours (h) in a microwave [19].
The irradiation from a microwave is electromagnetic irradiation, and for chemical synthe-
sis the most common frequency is at 2.45 GHz, corresponding to a wavelength of 12.25
cm. The energy produced by the microwave photon at this frequency is too low to cleave
molecular bonds. This means that, based on direct absorption of electromagnetic energy,
the microwave can not induce chemical reactions [19]. A solution to this is to use a solvent
or a reagent that absorbs microwave energy and converts it into heat [20]. Each solvent
converts a different amount of electromagnetic energy, due to different dielectric charac-
teristics. How much of the microwave energy that is absorbed depends on the degree of
penetration of microwaves in the solvent [20]. The more polar the reaction mixture is,
the greater it’s ability to absorb microwave energy. The loss tangent of a solvent is a
factor that tells you how efficient the electrical energy is converted into heat. The higher
the factor gets, the more energy is converted into heat. The loss tangent of 12 common
solvents is listed in Table 2.1 [21].
Table 2.1: Tan δ for 12 common solvents (measured at RT and 2.45 GHz) [21]
Solvent Tan δ Solvent Tan δ
Ethylene Glycol 1.350 Water 0.123
Ethanol 0.941 Acetonitrile 0.062
2-propanol 0.799 Acetone 0.054
1-propanol 0.757 THF 0.047
Methanol 0.659 Toluen 0.040
1-butanol 0.571 Hexane 0.020
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2.4 Flash column chromatography
Column chromatography is an intelligent and important purification and separation
method used in organic synthesis. The traditional and manual column chromatography
can be very time consuming, but the automated flash column chromatography speeds up
the process (Figure 2.3). The principle is based on pressurized gas that forces the solvent
and sample through the column. The flash column system often uses an ultraviolet (UV)
or infrared (IR) detector to detect the different peaks and analyze a sample [22].
Figure 2.3: Instrumentation of flash column chromatography
The most common stationary phase in the column is silica particles, but columns packed
with other particles can also be used. Based on the polarity of the sample, different
solvent systems can be used. Dichloromethane (DCM)/methanol and hexane/ethyl ac-
etate are some of the common mixtures of solvent, where one of the solvents has higher
polarity than the other. Higher polarity of the solvent increases the rate of elution of the
compounds in the sample that are being separated. The sample that is analyzed should
have a thin layer chromatography (TLC) Rf value of 0.15 to 0.20, in the solvent system
that is used in the flash column [22].
When the solvent is pushed through the column, all the compounds that absorb UV-light
will show as a peak in the display. Different compounds come out at different times based
on polarity, and for each compound, a peak will be made and lead to separation. The
different peaks can then be checked by TLC or LC-MS to confirm the identity of the
product. In this way, the different compounds in a sample are separated and purified.
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2.5 High performance liquid chromatography
High-Performance Liquid Chromatography (HPLC) is an analytical instrument that sep-
arates compounds and can identify each product in a mixture by using chromatographic
principles. Reverse-phase chromatography is the most common method, where the col-
umn is non-polar and the solvent is more polar. The most common column is a C18
column, that is packed with silica particles [23].
If the mobile phase is a mixture of water and an organic solvent, the elution strength of
the mobile phase will increase with an increasing percentage of organic solvent. When
the percent of organic solvent is increasing during a run, it is called a gradient. Different
compounds use different time through the column, based on the gradient and the polarity
of each compound [23]. Figure 2.4 shows the instrumentation of a HPLC instrument [24].
Figure 2.4: Instrumentation of HPLC [24]
In this project, the HPLC-instrument was used in the synthesis of a positron emmission
tomography (PET) tracer precursor. The aim was to seperate the products after the
methylation with radiolabelling. The HPLC was connected to a radioactivity detector,
so a possible 11C activity could be detected, in addition to separating the products.
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3 Method
3.1 Halogenation of imidazole
Halogenated imidazoles are of importance in a lot of chemical synthesis and medicinal
chemistry. Functionalization of imidazoles is important in transmetalation coupling reac-
tions to substitute the C-backbone of the imidazole skeleton [25]. Several procedures for
halogenation exist, and Bjorsvik et al . has described methods using both N,N’-diiodo-5,5-
dimethyl-hydantoin (DIH, 4) and iodine with potassium iodide as halogenation reagent.
DIH is activated by a strong Brønsteds acid, and iodine is reacting in the presence of a
strong base [26, 27]. The method using DIH selectively produces mono- or di-substituted
imidazole. This reaction is controlled by the addition and quantity of DIH and acid.
Scheme 3.1 shows the two different paths producing halogenated imidazole.
Scheme 3.1: Halogenation of imidazole with DIH, a) mono- b) di-substituted imidazole [26]
To selectively produce mono- or diiodoimidazole with DIH, is a very useful and powerful
method. In the preparation of monoiodoimidazole DIH and acid is mixed together and
added to the imidazole. In this was mostly one of the protons in the backbone will be
activated. For the diiodoimidazole preparation, DIH is first added to the imidazole, before
the acid is added dropwise, to activate both of the protons. The halogenated imidazole
can then be used in several different substitution reactions to produce larger molecules.
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3.2 Suzuki cross-coupling reaction
Cross-coupling reactions have been developed for many years, and through this develop-
ment, it is now possible to produce complex molecules. This is a highly selective reaction
and the result is carbon-carbon bonds between unsaturated organic compounds [28].
A Suzuki cross-coupling uses organoboron compounds to couple two hydrocarbon and
creates a carbon-carbon bond. The first step is an oxidative addition in which an or-
ganic electrophile (Ar1-X), reacts with the palladium catalyst. The second step is the
transmetalation between the product from the oxidative addition and an organometallic
reagent (Ar2-M). The last step to form the cross-coupled product (Ar1-Ar2) is a reductive
elimination [29]. Scheme 3.2 shows the catalytically cycle of the Suzuki-cross coupling.
Scheme 3.2: A catalytic cycle of the palladium-catalyzed Suzuki-cross-coupling reaction [28]
Boron compounds by themselves are neutral, have low reactivity and make the trans-
metalation limited. The poor nucleophilicity of boron compounds makes it difficult to
transfer the organic groups from boron to the palladium center. However, in 1979, Suzuki
and Miyaura disclosed a method that enhances the transmetalation. A Lewis base was
added to create an ”ate” complex (Scheme 3.3), of the boron complex [28].
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Scheme 3.3: Activation of the boron compound with a Lewis base [29]
This ”ate” complex is now more reactive than the neutral boron compound, and is able
to transfer the organic part to the palladium through transmetalation. The palladium is
now attached to two hydrocarbons and followed by reductive elimination a carbon-carbon
bond is formed. This completes the Suzuki cross-coupling reaction, and the palladium
catalyst can be reused in a new catalytic cycle [29].
3.3 N-methylation of nitroimidazole
Imidazoles by themselves are of great interest in many reactions and various biological
active compounds contain an imidazole in their structures [30]. The reactivity of the
imidazole can change by adding substituents to the ring. Either to one of the nitrogen,
in the backbone, in between the two nitrogens or a combination of them. One common
method is to methylate the nitrogen in the imidazole. From a medicinal chemistry per-
spective, this will decrease the amount of hydrogen bond donors and make it less polar.
This may also increase the lipophilicity of the final drug, which can be an advantage for
example to increase brain penetrations [31].
In most cases, a halogenated methyl compound is used in the preparation of N-methylimidazole.
In the presence of a base, the imidazole nitrogen will be deprotonated and the methyl











Scheme 3.4: General procedure for N-methylation of 2-nitroimidazole
3.4 Reduction of a NO2 compound
The reduction of nitro compounds is a well-known reaction and a very useful synthetic
transformation, leading to the corresponding amine. Different methods exist and one
of the most common uses hydrogen gas in the presence of palladium or platinum, as a
reducing agent [33]. Scheme 3.5 shows a general procedure for the reduction of a nitro
compound.
R NO2 R NO
+H2
-H2O
+H2 R NHOH +H2
-H2O
R NH2
Scheme 3.5: General mechanism of hydrogenation of a nitro-group [33]
Reducing the nitro compound to the corresponding amine makes it available for amida-
tion. The amidation is an important step in this project, due to the required amide linker
in the target molecule.
3.5 Synthesis of imidazole-5-yl-alkyl-1-ol derivatives
Functionalization of the backbone of the imidazole is of great interest in medicinal chem-
istry. Many coupling reactions exist and carbon-carbon bond formation is a well-known
reaction. In the synthesis of imidazole-5-yl-alkyl-1-ol derivatives, an aldehyde or ketone
is involved in the reaction. A base activates the backbone of the imidazole, and a new












Scheme 3.6: General scheme of the functionalization of the backbone of the imidazole with aldehyde
The formation of hydroxyalkylimidazole is an important reaction, leading to new com-
pounds. By using different derivatives of imidazole, a lot of different compounds can be
made. One example is to use 2-aminoimidazole and derivatives of that, in the reaction
with aldehydes or ketone [34]. From these derivatives, different coupling reactions, such
as amidation, can be performed.
3.6 Amidation
The synthesis of amides is of great interest in organic synthesis and medicinal chemistry.
Amides are present in many pharmaceuticals and bioactive natural compounds. For the
preparation of amides, several different methods exist. The most common way is to use
an amine and a carboxylic acid. This reaction requires high temperature because the
-OH is a poor leaving group. Scheme 3.7 shows the general reaction of an amidation.
R1 OH
O
+ R2 NH2 R1 NH
O
R2
Scheme 3.7: General scheme of an amidation
An option to avoid the high temperature is to use conditions that create a better leaving
group. One method involves the coupling reagent HATU that reacts with the carboxylic
acid and forms the ester. The amine can then react with the ester, forming the amide
bond and cleaving of a better leaving group. Scheme 3.8 shows the general mechanism


































Scheme 3.8: General mechanism for amidation with HATU [35]
Instead of using carboxylic acid as the reagent, a much more reactive compound is the
acid chloride. Chloride is a much better leaving group than the hydroxyl group and does
not require heat. The only reagent that is necessary in addition to the acid chloride, is










Scheme 3.9: General mechanism of amidation [36]
An amine is a good nucleophile, so the first step will be a nucleophilic attack on the
carbonyl. This forms the intermediate and the base removes a proton that neutralizes
the hydrochloric acid that is the by-product from the reaction. In the next step the
chloride leaves, due to better stability of an amide than the acid chloride [36].
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4 Results and discussion
Based on the previously synthesized molecule by Hodgetts et al ., the thiazole in the
molecule was replaced by an imidazole to make the target molecule (A/compound 14).
From an imidazole or an imidazole derivative as the starting material, several different
syntheses have been tried. The result of the different methods has led to the retrosynthesis
of the target molecule (Scheme 4.1). Disconnection of the amide bond of the target
molecule (A) gives the aryl acid chloride (B) and the 2-aminoimidazole derivative (C).
Further, the substituent on the backbone of 2-aminoimidazole was disconnected to give
a new derivative of 2-aminoimdazole (D). Oxidation of the 2-aminoimidazole gives the
corresponding nitroimidazole (E). A protonation of E gives the starting material, 2-



































Scheme 4.1: Proposed retrosynthesis for the target molecule. a) Amidation b) 2-aminoimidazole with
ketone, c) Reduction of nitro group, d) Methylation of 2-nitroimidazole
Before reaching the retrosynthesis (Scheme 4.1), other reaction routes were tried and are
also explained in the sections below. The synthesis path that is shown above has led to
many different analogs of the target molecule. Figure 4.1 shows the different analogs that
were made of the target molecule. Different substituents were used in the backbone of
the imidazole, and two different aromatic substituents were attached to the carbonyl in














, , CH3 ,   H,
Figure 4.1: All of the analogs that were made of the target molecule
4.1 Synthesis of 1-methyl-1H -imidazole (1)
Substitution on the imidazole can change the activity of the compound. Methyl is a
common substituent and a good electrophile. Methylation of the imidazole was there-
fore a good option to change the activity of the imidazole. Several procedures for the
methylation of imidazole exist. The most common way is to use a halogenated methyl
compound and a good base. The reaction time is not too long and is carried out under
low temperature.
Imidazole, potassium hydroxide and acetone were mixed together and when the temper-
ature reached 3 oC, methyl iodide was added dropwise to the mixture. The result will be
a deprotonated imidazole, with the methyl group attatched to the nitrogen. Scheme 4.2










Scheme 4.2: Reaction scheme for the synthesis of 1-methyl-1H -imidazole (1)
1H NMR and LC-MS analysis was performed and confirmed conversion and a good yield
after workup (84 %). LC-MS indicated that the isolated product contained iodine. This
was seen at the LC-MS spectrum in negative ESI, where the peak with a m/z of 126.9
is equivalent to the adduct ion [M-H+] of iodine and corresponds to iodine. Figure 4.2
shows the LC-MS spectrum of the crude product.
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Figure 4.2: MS spectrum in positive and negativ ESI of 1-methyl-1H -imidazole (1). m/z of 83.1
corresponds to the product, whereas m/z of 126.9 corresponds to iodine
The 1H NMR spectrum of compound 1 (Figure 4.3) shows a clean product, with some
traces of contaminated CDCl3 (2.63, 2.18 and 1.26 ppm). The three protons in the aro-
matic region, (7.44, 7.05, 6.89 ppm) represent the hydrogen in between the two nitrogens
and the two in the backbone of the imidazole. The last peak that is more upfield in the
spectrum (3.59 ppm), represent the three protons in the methyl group attached to the
nitrogen.
Figure 4.3: 1H NMR spectrum of 1-methyl-1H -imidazole (1)
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4.2 Synthesis of 1-(1-methyl-1H -imidazol-2-yl)cyclobutan-
1-ol (2)
Based on the previously synthesized probe, the best result was obtained when the thiazol
was substituted with a hydroxyl group and a cyclobutyl group. For the imidazole, the
2-position is one of the easiest places to substitute the molecule, and the chosen position
for this substituent. This is because the electrons there are most loosely bounded, due
to the two nitrogens that are electron-withdrawing and are pulling the electrons. Several
procedures for this substitution exist and a reaction with n-BuLi is a powerful method








0 ℃, 45 min
O




Scheme 4.3: Reaction scheme for synthesis of 1-(1-methyl-1H -imidazol-2-yl)cyclobutan-1-ol (2)
In the preparation of 1-(1-methyl-1H -imidazol-2-yl)cyclobutan-1-ol (2), methylimidazole
(1) and n-BuLi was stirred for 45 min under very low temperature. This created a lithium
intermediate that reacted with cyclobutanone for 45 min to complete the reaction.
The reaction gave conversion and a good yield with some impurities (68 %). LC-MS
analysis indicated that the isolated product contained a small trace of the starting ma-
terial. This was seen as the LC-MS spectrum in positive ESI consisted of a small peak
that corresponds to the m/z of the starting material. This peak has an m/z of 83.1,
equivalent to the adduct ion [M+H+] of the starting material. However, the main peak
in the spectrum has an m/z of 153.1 that corresponds to the product. The product was
not purified, so the yield is not completely accurate.
22
4.3 Synthesis of 4(5)-iodo-1-methyl-1H -imidazole (3)
In the target molecule of this project, the cyclobutyl substituent is attached in the back-
bone of the imidazole. Therefore the new approach was to halogenate the backbone and
try different substitution reactions. Bjørsvik et al . [26] disclosed a palladium-catalyzed
method for halogenation of imidazole. This is a selective halogenation method that can
substitute only one or both of the carbons in the backbone. Substitution at the N-position
in the imidazole can sometimes be an issue when it comes to reactivity. This was dis-









Scheme 4.4: Reaction scheme for synthesis of 4(5)-iodo-1-methyl-1H -imidazole (3)
In the preparation of 4(5)-iodo-1-methyl-1H -imidazole (3), methylimidazole (1) was dis-
solved in H2O and NaOH, and reacted with a mixture of DIH and sulphuric acid. This
reaction gave no conversion and both 1H NMR and LC-MS analysis confirmed starting
material in the crude product. The target molecule was not observed. Different types of
halogenation reagents, iodine monochloride and KI, and I2, have also been tried but gave
no conversion.
4.4 Synthesis of 4(5)-iodo-1H -imidazole (4)
Based on the results from the synthesis of compound 3, the procedure from Bjørsvik
et al . [26] was carried out in the same manner as the article described, using imidazole


















Scheme 4.5: Reaction scheme for the two step synthesis of 4(5)-iodo-1H -imidazole (4) with DIH as an
iodinating agent
NaOH, water and imidazole were added together and cooled down. Sulphuric acid was
added to DIH and mixed together before added to the mixture with imidazole. This is a
very fast reaction and a good method for halogenation of imidazole at the backbone.
1H NMR and LC-MS analysis confirmed conversion and a good yield after workup (49 %).
The 1H NMR spectrum of compound 4 reveals two singlets in the aromatic region (9.12
and 7.81 ppm) and two peaks more upfield (2.51 and 1.25 ppm) that is not explained
yet. LC-MS spectrum (Figure 4.4) confirmed the product with a molecular mass of 194
g/mol. This corresponds to the positive ESI spectrum with a peak that has an m/z of
195.0 and negative ESI spectrum with a peak that has an m/z at 193.0.
Figure 4.4: MS spectrum in positive and negativ ESI of 4(5)-iodo-1H -imidazole (4). m/z of 195.0
(+ESI) and 193.0 (-ESI) corresponds to the product, whereas m/z of 320.9 (+ESI) and
318.9 (-ESI) corresponds to 4,5-diiodoimidazole
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The LC-MS spectrum also indicated that the product contained the 4,5-diiodoimidazole
compound, due to a small peak with an m/z at 320.9 in positive ESI and a big peak
with m/z at 318.9 in negative ESI. This corresponds to the mass at 319 g/mol for 4,5-
diiodoimidazole. In this type of halogenation of imidazole, it is normal to see both
mono- and diiodoimidazole in the product. This is due to two identical hydrogens at the
backbone, where both of them can be exchanged.
4.5 Synthesis of 4-cyclobutyl-1H -imidazole (5)
Several coupling reactions for carbon-carbon bond formation exist. The Suzuki coupling
is one example that is used for bond formation in imidazole. Bjørsvik et al . [38] disclosed
a Suzuki-cross coupling reaction with imidazole, producing aryl-substituted imidazole.
This type of Suzuki-cross coupling has not been achieved using cycloalkyl boronic acids
and was therefore interesting to try.
The reaction involves a boron compound, in this case, a boronic acid, and an organic
electrophile. To activate the boron compound, a base needs to be present in the reaction.
In this case two different bases have been tried, K2HPO4 and K2CO3. A catalyst, in this
case, Pd(PPh3)4, was used to increase the rate of the reaction together with the use of a
microwave.
Different attempts on the suzuki coupling were performed using different reagents, tem-
peratures, reaction times and approaches. The first two attempts (Table 4.1) were carried
out using the procedure from Bjørsvik et al . [38] and the rest followed the procedure from
Zeng et al . [39], with some changes in solvent, base and reaction time. Two of the re-
actions were carried out in an oil bath over a longer time, to see if that was the best
approach. The temperature was also adjusted, but that did not change the outcome of
the reaction. None of the reactions in Table 4.1 gave conversion and the target molecule
was not observed.
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Table 4.1: Experimental table for the Suzuki-cross coupling in the synthesis of 4-cyclobutyl-1H -
imidazole (5)
Number Substituent, R Temperature (oC) Time (h) Approach Base Solvent Result
1 H 100 1 µw K2HPO4 MeOH NC
2 Tos 100 1 µw K2HPO4 MeOH NC
3 H 100 1 µw K2CO3 Toluen NC
4 H 120 1 µw K2CO3 Toluen NC
5 H 120 23 Oilbath K2CO3 Toluen NC
6 H 120 1 µw K2CO3 MeOH NC
7 H 130 2 µw K2CO3 EtOH NC
8 H 130 48 Oilbath K2CO3 EtOH NC
4.6 Synthesis of 4-iodo-1-tosyl-1H -imidazole (6)
Protective groups on imidazole are necessary in many reactions, due to high reactivity
on the proton in the nitrogen. This can then react with other reagents, and produce
unwanted products. Tosyl is a common protective group and has been used several
times in Bjørsviks groups in the synthesis with imidazole. Scheme 4.6 shows the general













Scheme 4.6: Reaction scheme for the synthesis of 4-iodo-1-tosyl-1H -imidazole (6)
4-(5)-iodoimidazole (4), TosCl, dry THF and Et3N were mixed together and stirred for
4 h in RT. The crude product was re-crystalized with DCM in a yield of 42 %. 1H NMR
spectrum was in accordance with the literature [27].
26
4.7 Synthesis of 1-(1-tosyl-1H -imidazole-4-yl)cyclobutan-1-ol with
n-Buli (7)
From the synthesis of compound 2, we know that the reactivity of nBuLi with imidazole
works well and gave the desired product. An exchange of iodine with lithium is a very
fast transmetalation, that is used to prepare lithium reagents [40]. To try and get the
substituent at the backbone instead of the in second position, compound 6 was used as
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Scheme 4.7: Reaction scheme for the two-step synthesis of 1-(1-tosyl-1H -imidazole-4-yl)cyclobutan-1-
ol (7)
Compound 6 and n-BuLi was used to prepare the lithium reagent under very low temper-
ature, before reacting with the cyclobutanone for 1 h. In this reaction, the best outcome
would be if the iodine and lithium exchange took place at the backbone. This was not
the case and LC-MS analysis did not show any peak of the target product. An LC-MS
sample of the intermediate was also checked but did not show the right peak. The desired
product was not observed.
4.8 Synthesis of 1-(2-amino-1H -imidazol-4-yl)ethan-1-ol (8)
Since the reaction above did not give the desired product, a new approach was tried.
This time the starting material was 2-aminoimidazole, trying to substitute the backbone.
Reactions of 2-aminoimidazole with the intention of substitute the backbone has not
been described much in the literature. Horne et al . [34] published an article in 1993
about 2-aminoimidazole and aldehydes to prepare hydroxyalkylaminoimidazole and other

















Scheme 4.8: Reaction scheme for the synthesis of 1-(2-amino-1H -imidazol-4-yl)ethan-1-ol (8)
In the preparation of compound 8, 2-aminoimidazole was dissolved in water and sodium
carbonate was added. After 10 min acetaldehyde was added and the reaction stirred for 4
h. After the reaction, LC-MS analysis (Figure 4.5) was performed and confirmed product
formation (m/z = 128.1), but showed mainly starting material (m/z = 84.1). Automated
flash chromatography was used to separate the products, but the desired product was
not able to be isolated.
Figure 4.5: MS spectrum of 1-(2-amino-1H -imidazol-4-yl)ethan-1-ol (8). m/z of 128.1 corresponds to
the product, whereas as m/z of 84.1 corresponds to the starting material
A new reaction was set up and the conditions used in the procedure were modified, and
described in Table 4.2. Different reaction times and temperatures were changed to try to
increase the yield of the desired product.
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Experiment Time (h) Temperature (oC) Result, LC-MS
1 4 RT peak observed, mostly SM
2 19 RT peak observed, mostly SM
3 4 60 peak observed, mostly SM
4 17 60 NC
As Table 4.2 shows, the desired product was observed in most cases, but the main peak
in the LC-MS spectra was the starting material. The changes showed in Table 4.2 did
not increase the yield of the desired product, so the method had to be modified. From
previously synthesis, we know that substitution on the nitrogen in the imidazole can
change the reactivity of the compound. The next approach was then to substitute the
nitrogen in the imidazole, and then try the same reaction.
4.9 Synthesis of 1-methyl-2-nitro-1H -imidazole (9)
Direct methylation of the starting material used in the synthesis of compound 8, will lead
to methylation of both the amine group and nitrogen in the imidazole. Due to this, the
next step will be to methylate 2-nitroimidazole. Several procedure for the methylation
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Scheme 4.9: Schematic prosedure for the preparation of 1-methyl-2-nitro-1H -imidazole (9)
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In the preparation of compound 9, 2-nitroimidazole and Cs2CO3, were dissolved in MeCN
and iodomethane was added dropwise to the mixture at O oC. After 1 h LC-MS analysis
was performed and confirmed product formation. The product was purified with silica
gel column chromatography, to give the title compound as white solid, in a good yield
(68 %). 1H NMR analysis confirmed the product and the spectrum was in accordance
with the literature [32].
4.10 Synthesis of 1-methyl-1H -imidazole-2-amin (10)
The reduction of a nitro-group is a well-known method and several procedures exist. One
of the most common uses palladium in the presence of hydrogen gas to reduce the nitro












Scheme 4.10: Schematic prosedure for the preparation of 1-methyl-1H -imidazole-2-amin (10)
In the preparation of compound 10, compound 9 and Pd(OH)2 were dissolved in ethanol
and equipped with a H2 gas ballon. The reaction stirred overnight and LC-MS analysis
confirmed the conversion. After workup the title compound did not need any further
purifications, to give the title compound in a good yield (63 %). 1H NMR analysis
confirmed the product and the spectrum was in accordance with the literature [42].
4.11 Synthesis of backbone substituted amino imidazole (11-13)
Due to almost no conversion and low yield of compound 8, it was decided to do the
reaction with a substituent at the nitrogen. The reaction was carried out in the same
manner as for compound 8, having compound 10 as the starting material. A methyl group
at the nitrogen was added, to see if that made the compound more reactive. Scheme 4.11
















Scheme 4.11: Reaction scheme for the synthesis of 1-(2-amino-1-methyl-1H -imidazol-4-yl)ethan-1-ol
(11)
In the preparation of compound 11, the same amount and same equivalents as for com-
pound 8 were used, and stirred overnight. After 19 hours LC-MS analysis was performed
and showed a good conversion of the product, but there was still some unreacted starting
material. A new amount of Na2CO3 and acetaldehyde, the same equivalents as in the
beginning, was therefore added and LC-MS was checked again after 24 h. LC-MS showed
more conversion and the same amount of the same reactants were added one more time,
and the reaction stirred overnight. After 48 h the reaction showed full conversion of the
product (m/z=142.1 in Figure 4.6), with some impurities, as was seen in the LC-MS
spectrum (Figure 4.6).
Figure 4.6: LC-MS spectrum of 1-(2-amino-1-methyl-1H -imidazol-5-yl)ethan-1-ol (11)
Table 4.3 show different attempts of the preparation of compound 11, where the equiv-
alents of sodium carbonate and the aldehyde have been modified. Based on the first
attempt described above, different amounts of the reagents have been tried to reduce
the reaction time of 43 h. The only experiment that gave full conversion after 24 h was
number 7 where the total amount of Na2CO3 and acetaldehyde from experiment number
1 was added at the beginning of the reaction.
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Table 4.3: Experimental table for synthesis of compound 11
Experiment Time (h) Na2CO3(mmol) CH3CHO(mmol) Result, LC-MS
1 48 0.6+0.6+0.6 1.2+1.2+1.2 Mostly product
2 30 1.2 2.6 Mostly product, SM observed
3 24 1.5 2.8 Mostly product, SM observed
4 24 1.2 2.8 Mostly product, SM observed
5 24 0.6 3.0 Mostly product, SM observed
6 24 2.0 3.0 Mostly product, SM observed
7 24 1.8 3.6 Mostly product
Even if the reaction gave full conversion, some side-products was formed in the reaction.
The crude product was tried purified with silica gel column chromatography, but isolation
of the product was not accomplished. Due to no purifications and some contaminations
present in the product, an accurate yield can not be given.
Based on the result of the preparation of compound 11, a few more analogs were prepared.
They were carried out in the same manner as with compound 11, but with a change
of reagent. Table 4.4 shows the different reagents that were used and the resulting
substituents.



















Isobutyraldehyde was used instead of acetaldehyde, to make a more branched alcohol in
the backbone. The LC-MS analysis of this reaction did not show full conversion, but the
target molecule had the highest peak in the LC-MS spectrum (m/z=170.1) (Figure 4.7).
Isobutyaldehyde is a more branched aldehyde, which makes it more steric hindered in the
reaction and may be the reason for not a full conversion. Isolation of the product was
not accomplished, but product formation was confirmed and the crude mixture was used
directly in the next step.
Figure 4.7: LC-MS spectrum of 1-(2-amino-1-methyl-1H -imidazol-5-yl)-2-methylpropan-1-ol (12)
Based on the procedure from Horne et al . [34], an aldehyde was used as reagent to
prepare compound 11 and 12. To achieve the analog of the compound that Hodgetts
et al . synthesized, a ketone was the only option as a reagent. Based on the literature, it
is difficult to find a procedure using a ketone instead of an aldehyde. This was therefore
an interesting investigation, leading to new and good results. Also here the reaction did
not show full conversion, even if the reaction time was longer and was carried out with
heat. The target molecule (13) was observed and the crude mixture was used in the next
step without any purifications.
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4.12 Synthesis of amide analogs (14-27)
Several procedures for an amidation exist. The standard method involves a carboxylic
acid and an amine. Hodgetts et al . [3] used carboxylic acid and aniline in the presence
of the coupling agent HATU, to create the amide bond in their synthesized molecule.
Another option is to use acid chloride instead of carboxylic acid and HATU. The acid
chloride is more reactive then carboxylic acid, and chloride is a better leaving group in
the coupling with the amine.
Synthesis of compound 14 and 15
Scheme 4.12 shows the general procedure for the first attempt of amidation used in the
synthesis of compound 14. Compound 11 was dissolved in dichloroethane, TEA and the
acid chloride was added. The reaction stirred for overnight at 70 oC. After the reaction,
LC-MS analysis was performed and showed a peak with an m/z of 280, which is a loss
of m/z = 18 from the desired product. The product was purified with silica gel column
chromatography with a mixture of hexane and ethyl acetate, with a 100:0 % - 50:50 %



















Scheme 4.12: Synthesis of 3-chloro-4-fluoro-N -(4-(1-hydroxyethyl)-1H -imidazol-2-yl)benzamide (14)
Based on the loss of m/z = 18 and the existence of a hydroxyl group in the starting
material, there was a possibility that the alcohol has been eliminated and an alkene was
formed. An elimination happens in the presence of heat, which was the case in this
reaction. This means that the alcohol was most likely eliminated to an alkene. This
assumption corresponds well with the LC-MS analysis, where the peak shows a loss of
water, which occur during the elimination.
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The 1H NMR spectrum (Figure 4.8) also indicates that the alkene was formed, due to
more peaks in the aromatic region than the desired product was supposed to have. The
most downfield peak (12.45 ppm) represents the hydrogen at the amide, and the next
three peaks in the aromatic region represent the three protons in the benzene ring (8.22,
7.42 and 7.11 ppm). In addition to this, there was no sign of the hydrogen in the alcohol,
instead, there were three peaks, two doublets (5.32 and 5.76 ppm) and one triplet (6.61
ppm) that corresponds well with the three protons in an alkene.
Figure 4.8: 1H NMR spectrum of 3-chloro-4-fluoro-N -(1-methyl-5-vinyl-1H -imidazol-2-yl)benzamide
(15)
Another observation was that there was just one peak (3.58 ppm) that represents a methyl
group, instead of two that the desired product was supposed to have. This confirms that
compound 15 was synthesized instead of compound 14. A new method was developed
for the preparation of compound 14. Scheme 4.13 shows the two different amidation































Scheme 4.13: Two different methods for the amidation in the synthesis of compound 14 and 15
In the preparation of compound 14 the reaction was carried out in room temperature
instead of 70 oC. The solvent was changed to DCM and the equivalent of the acid chloride
was also reduced from 2.2 mmol to 1.0 mmol. After stirring for 30 min, LC-MS analysis
showed full conversion. Mostly the product was formed, but a small peak in the LC-MS
spectrum showed that the alkene was formed too. The two products were separated
and purified with silica gel column chromatography with a mixture of DCM and MeOH
on a 100:0 % - 90:10 % gradient. The 1H NMR spectrum of the product showed some
impurities, so the product was completely purified with crystallization with DCM.
After the crystallization the 1H NMR spectrum (Figure 4.9), shows a clean product. In
the downfield part of the spectrum, you will find the hydrogen at the amide (12.12 ppm)
and in the aromatic region, you will see the three hydrogens at the phenyl (8.23, 8.12
and 7.42 ppm) and the hydrogen at the backbone of the imidazole (6.68 ppm). More
upfield in the spectrum, you will find the hydrogen in the alcohol and the hydrogen in
the secondary carbon, which are the differences from the spectrum of the alkene. In
addition to this, you can see the hydrogens in both of the methyl groups in the upfield
part of the spectrum (3.57 and 1.42 ppm), which was a strong indication that the right
molecule was prepared.
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Figure 4.9: 1H NMR spectrum of 3-chloro-4-fluoro-N -(5-(1-hydroxyethyl)-1-methyl-1H -imidazol-2-
yl)benzamide (14)
Since the starting material for the amidation, compound 11, was not pure, a 1H NMR
analysis was not performed. Due to this, it was difficult to determine in which position of
the backbone the substituent was attached. A more detailed NMR analysis was therefore
collected of the target molecule (compound 14). Based on the chemistry of the methyl-
imidazole, the substituent was most likely attached to the 5th position, closest to the
nitrogen with the methyl group. To confirm this, a NOESY spectrum of the final product
(compound 14) was collected (Figure 4.10).
Figure 4.10: NOESY spectrum of 3-chloro-4-fluoro-N -(5-(1-hydroxyethyl)-1-methyl-1H -imidazol-2-yl)
benzamide (14)
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In the NOESY spectrum you can see interactions between the different hydrogens in
the molecule. Hydrogens that are close to each other will interact and produce a spot
in the spectrum. A good example is the hydrogen in the backbone of the imidazole
and the hydrogen in the methyl group in the backbone. They are close to each other
and will therefore produce a spot that is shown in the NOESY spectrum in Figure 4.10
(red square). Based on the two options of attachment for the substituent, the NOESY
spectrum will show different interactions. If the substituent is attached in the 4-position
in the backbone, the hydrogen in 5-position would be interacting with the methyl group
in the nitrogen. The spectrum does not show any interactions between these hydrogens
(green square). However, the spectrum shows a weak interaction between the methyl
group in the substituent and the methyl group in the nitrogen (blue square). This means
that the substituent in the backbone is close to the methyl group in the nitrogen, and is
most likely attached to the imidazole in the 5th position.
Based on the result of the amidation of compound 11, compound 12 and 13 were also
used in amidation, to produce analogs of the target molecule. The reactions were carried
out in the same manner as for compound 14. Table 4.5 shows the different analogs that
were made.
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Synthesis of compound 16
In the preparation of compound 16, compound 12 was used directly without any purifi-
cation. Since the crude product still contained some starting material (compound 10),
the expected result will be to get two products after the amidation. After 1 h of stirring
in RT, the reaction showed full conversion. The crude reaction mixture was analyzed by
LC-MS and confirmed the assumption that two products were formed. The spectrum
showed mainly two peaks, one with an m/z at 326.1 and one with an m/z at 254.1, which
represent the two molecules in Figure 4.11. The two products were successfully separated
with silica gel column chromatography and the desired product was crystallized with a
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16
Figure 4.11: Product (16) and side-product produced in the preparation of compound 16
The 1H NMR spectrum of the isolated product (Figure 4.12), indicates a clean prod-
uct with no impurities. The main difference in this spectrum compared to the one of
compound 14, is that there is more peaks in the upfield part due to more carbon and
hydrogens in the backbone of the imidazole. The two doublets (0.97 and 0.81 ppm) repre-
sent the two methyl groups and the multiplet (1.98 ppm) represents the hydrogen in the
tertiary carbon. The rest of the peaks more downfield in the spectrum are very similar
to the spectrum of compound 14.
Figure 4.12: 1H NMR spectrum of 3-chloro-4-fluoro-N -(5-(1-hydroxy-2-methylpropyl)-1-methyl-1H -
imidazol-2-yl)benzamide (16)
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Synthesis of compound 17
In the preparation of compound 17, the amidation was carried out in the same manner
as with compound 14 and 16. Also here the crude product of compound 13 was used
directly without any purifications, which means that it contains both the starting ma-
terial (compound 10) and the product (compound 13). In the amidation both of these
compounds will be available for coupling reaction and the crude product will most likely
contain two compounds. One of the compounds will be the desired product and the other
one will be the same side-product that is shown in Figure 4.11 (p. 40). The LC-MS anal-
ysis of the crude mixture (Figure 4.13) confirms formation of both the side-product (m/z
= 254.0), and the desired product (m/z = 324.1). Silica gel column chromatography was
used to purify and separate the two products, with a mixture of DCM/MeOH (100:0 %
- 90:10 % gradient).
Figure 4.13: LC-MS spectrum of the crude mixture of 3-chloro-4-fluoro-N -(5-(1-hydroxycyclobutyl)-1-
methyl-1H -imidazol-2-yl) benzamide (17)
The 1H NMR spectrum of compound 17 (Figure 4.14) is very similar to the spectrum of
compound 14 and 16. The aromatic region has the same peaks, due to the same phenyl
ring in the amide and one hydrogen in the backbone of the imidazole. The main difference
is in the downfield part of the spectrum. For compound 17, there will be more peaks in
this area, due to more hydrogens in different chemical environment for the cyclobutyl.
The four multiplets most downfield represent the six hydrogens in the cyclobutyl that is
attached in the backbone of the imidazole.
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Figure 4.14: 1H NMR spectrum of 3-chloro-4-fluoro-N -(5-(1-hydroxycyclobutyl)-1-methyl-1H -
imidazol-2-yl)benzamide (17)
Synthesis of compound 18
In addition to compound 14-17, an analog without any substituent on the backbone of
the imidazole, compound 18 in Table 4.5, were also made. This was a one-step amidation
reaction with 1-methylimidazole-2-amin, and the preparation was carried out in the same
manner as for compound 14-17. LC-MS analysis confirmed product formation and the
product was purified with crystallization with ethyl ether to give the title compound in
an overall yield of 38 %.
The 1H NMR spectrum (Figure 4.15) of compound 18 is also very similar to the spectra
of compound 14-17. The main difference is that compound 18 does not have any sub-
stituents in the backbone, and will therefore have two hydrogens instead of one hydrogen
in the backbone. This will give an extra peak in the aromatic region in addition to all
the other peaks that are similar to the other spectra. Due to no substituents, there will
not be any peaks in the most upfield region of the spectrum.
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Figure 4.15: 1H NMR spectrum of 3-chloro-4-fluoro-N -(1-methyl-1H -imidazol-2-yl)benzamide (18)
Synthesis of compound 19-23
From the different compounds Hodgetts et al . [3] have been tested, they tried different
aromatic compounds in the amide bond. The one that gave the best results was with
chloride and fluoride in the 5th and 3rd position of the phenyl ring. Now when the thiazole
is replaced with an imidazole, that might change the activity and the aromatic ring with
two substituents might not be the best option anymore. Based on this compound 14-18
were also synthesized without any substituent on the aromatic ring, only a phenyl ring.
This lead to compound 19-23 in Table 4.5 (page 39).
Compound 19-23 were synthesized in the same manner as for compound 14-18, with
a new acid chloride. Benzoyl chloride was now used to prepare compounds with the
aromatic substituent as a phenyl ring without any substituent. The 1H NMR spectrum
of compound 19 is almost identical to the one of compound 14. The only difference
is that compound 19 has five protons in the aromatic region instead of three which
compound 14 has. This will be the case for compound 15-18 as well. The 1H NMR
spectrum of compound 19 (Figure 4.16), shows that the aromatic region contains five
protons, instead of three. The other peaks are similar to compound 14 and will represent
the same hydrogens.
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Figure 4.16: 1H NMR spectrum of N -(5-(1-hydroxyethyl)-1-methyl-1H -imidazol-2-yl)benzamide (19)
Synthesis of compound 24-27
All of the analogs described above have a methyl group as a substituent on the nitro-
gen in the imidazole. From the previously synthesized molecule by Hodgetts, neither
the nitrogen nor the sulfur in the thiazol had any substituents. It would therefore be
an interesting approach to make a few analogs without any N-substitution in the imi-
dazole. Two different molecules were used as starting material, 2-aminoimidazole and
5-methylimidazole-2-amine. From these two compounds, four new analogs were made.
All of them were synthesized in the same manner as for the compounds in Table 4.5 (page
39). Table 4.6 shows the different substituents and products.































In the preparation of the compounds in Table 4.6, the reaction showed almost full conver-
sion, due to a one-step reaction. Compound 24 had low solubility in DCM and was not
able to be purified with silica gel column chromatography. However, extraction with ethyl
acetate instead of DCM gave a pure product. LC-MS and 1H NMR analysis confirmed
product formation and a clean product in an overall yield of 36 % (86 mg). Compound
25 was purified with silica gel column chromatography and crystallized with ethyl ether
to give the title compound as a pure product in a overall yield of 8 % (19 mg).
The 1H NMR spectrum of compound 25 (Figure 4.17) has the same peaks in the aromatic
region of the spectrum as for compound 14-17. The most downfield peak will now
integrate into two instead of one, due to the proton in the nitrogen in the imidazole in
addition to the proton in the amide. The upfield part of the spectrum will only have
the three hydrogens in the methyl group at the backbone of the imidazole. The chemical
shift of these protons will be more downfield than the methyl group in the nitrogen due
to less shielding from a carbon instead of nitrogen.
Figure 4.17: 1H NMR spectrum of 3-chloro-4-fluoro-N-(5-methyl-1H-imidazol-2-yl)benzamide (25)
For compound 26 and 27 purification was a problem, due to low solubility in DCM. Silica
gel column chromatography was used to purify the products. Compound 27 gave the best
yield (12 %, 23 mg) but the yield of the purified product for compound 26 was lower
(6 %, 11 mg). Different crystallization methods were also tried but did not completely
purify the products.
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Result from preliminary testing
All of the compounds described above were synthesized and tested at the Department of
Dermatology, Indiana University School of Medicine. Based on the testing, the result is
presented by an EC50 value and % activation. The EC50 value describes the concentration
of the molecule that gives the half-maximum response or % activation. A lower EC50 value
and higher % activation makes a better and more potent compound. Table 4.7 shows the
different molecules that were tested, with the corresponding EC50 value and % activation.
Table 4.7: Analogs that are synthezised and tested, with the corresponding EC50 value and % activation








































































































Based on the results from the previously tested molecule (LDN-27), compound 17 was
the target molecule and was expected to be active. The result was compared with com-
pound LDN-27, and compound 17 turned out to be inactive. However, compound 15
showed good activity (158 %) and a low EC50 value (0.45). Figure 4.18 shows the %
activation and the EC50 value presented in graphs for the three compounds (LDN-27,
compound 17 and compound 15).
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Figure 4.18: Results of the previously tested molecule (LDN-27) and compound 15 and 17
Compounds with low % activation and high EC50 value (compound 18), will not be good
and potent molecules, because you do not want a high concentration of the drug at the
half-maximum response. Figure 4.19 shows the different substituents that have been used
in the synthesized molecules. A summary of the results shows that a methyl group at the
nitrogen, an aryl ring with chloride and fluoride as substituents attached to the carbonyl
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Figure 4.19: Summary of the result from the preliminary testing
The conclusion of this testing will therefore be that compound 15 is the most potent
molecule, but due to the alkene, it might not be the best solution as a drug. If you
compare it to the previously synthesized molecule (LDN-27), the EC50 value is almost
the same, but the % activation is a bit lower for compound 15. This means that further
optimization can be done, either to make this compound more potent or synthesized
analogs that are more active. One option is to change the substituents on the phenyl
ring. Another change can be to try other substituents on the nitrogen and the backbone
of the imidazole. In the nitrogen, it would be interesting to try a phenyl ring or a longer
carbon chain, for example, ethyl instead of a methyl group. At the backbone, it would
also be interesting to try a longer carbon chain without the alcohol or a phenyl ring.
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4.13 Synthesis of 1-benzyl-2-nitro-1H -imidazole (28)
In this project, most of the analogs have a methyl group at the nitrogen in the imidazole.
By changing this to a benzyl group, more analogs can be made. The preparation of
compound 28 was carried out in the same manner as for compound 9, using benzyl














Scheme 4.14: Schematic prosedure for the preparation of 1-benzyl-2-nitro-1H -imidazole (28)
In the preparation of compound 28, 2-nitroimidazole and Cs2CO3 were dissolved in ace-
tonitrile and cooled down in an ice bath. Benzyl bromide was added dropwise before
the reaction stirred with reflux at 65 oC for 1 h, to give the crude mixture containing
the product. The product was purified with silica gel column chromatography with a
mixture of hexane/ethyl acetate, to give the title compound in a yield of 43 % (88 mg).
Both LC-MS and 1H NMR analysis confirmed a clean product. Figure 4.20 shows the 1H
NMR spectrum of compound 28.
Figure 4.20: 1H NMR spectrum of 1-benzyl-2-nitro-1H -imidazole (28)
48
The 1H NMR spectrum (Figure 4.20) shows the five hydrogens in the phenyl (7.38 and
7.21 ppm) and the two hydrogens in the backbone of the imidazole (7.17 and 7.05 ppm)
in the aromatic region. The two hydrogens more upfield (5.60 ppm) represent the two
hydrogens in the benzylic position.
4.14 Synthesis of 1-benzyl-1H -imidazole-2-amin (29)
To reduce compound 28 to the corresponding amine, the presence of Palladium (Pd) will
cleave off the benzyl at the nitrogen. Instead of using Pd as a catalyst, iron powder was
used in the presence of acetic acid. The reaction time had to be increased, compared
to the reduction with H2 gas and Pd, to prepare the title compound (29). Scheme 4.15











Reflux, 70℃, 3 days
Scheme 4.15: Schematic prosedure for the preparation of 1-benzyl-1H -imidazole-2-amin (29)
In the preparation of compound 29, compound 28 was dissolved in ethanol and water,
before iron powder and acetic acid was added. After three days at 70 oC with reflux, LC-
MS analysis was performed and showed full conversion. The product was tried purified on
silica gel column chromatography, but the desired product was not able to be separated.
Due to no purifications and some contaminations present in the product, an accurate
yield cannot be given.
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4.15 Synthesis of 1-(2-amino-1-benzyl-1H -imidazol-5-yl)ethan-
1-ol (30)
Based on the results on the preparation of compound 11-13, another analog was possible
to make. As we know from before, the substituent on the nitrogen in the imidazole may
change the activity of the imidazole. We know that the reaction works well with a methyl
group at the nitrogen, but we do not know what will happen with a benzyl group attached
to the nitrogen. Compound 29 was used to prepare compound 30, in the same manner
















Scheme 4.16: Schematic prosedure for the preparation of 1-(2-amino-1-benzyl-1H -imidazol-5-yl)ethan-
1-ol (30)
After 24 h LC-MS analysis was performed and the desired product and the starting
material were not observed. Some side-reactions may have happened, producing other
compounds. The benzyl group is most likely the reason the backbone substitution did
not happen. The benzyl may be more reactive, and reactions may have happened there
instead of in the backbone of the imidazole.
4.16 Synthesis of 3-chloro-N -(1,5-dimethyl-1H -imidazol-2-yl)-
4-fluorobenzamide (31)
Another part of this project was to see if some of the compounds worked as PET tracer
precursors. This means that one part of the molecule needs to have a radioactive atom,
making them active in PET analysis. In this project, the radioactive part was a 11C
in form of a CH3-group. To achieve this, the last step of the synthesis had to be the
methylation of the N-H in the imidazole. Some of the synthesized compounds have a free
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N-H, leaving them as a good option. With methylation in a ”hot cell” with [11C]CH3,
it might be possible to make them as PET tracer precursors. Compound 25 was a
good option to choose for a precursor. Before doing the methylation in the ”hot cell”
introducing the [11C]CH3, the synthesis needs to work with regular CH3I. Figure 4.21





















Figure 4.21: Schematic procedure for the synthesis of 3-chloro-N -(1,5-dimethyl-1H -imidazol-2-yl)-4-
fluorobenzamide (31)
In the preparation of compound 31, compound 25 and Cs2CO3 were dissolved in acetoni-
trile and iodomethane was added dropwise at O oC. The reaction stirred with reflux at 60
oC for 1 h, to give the crude mixture containing the product. The product was purified
with silica gel column chromatography with a mixture of hexane and ethyl acetate. The
product was crystallized with ethyl ether, to give the title compound in a yield of 18 %
(23 mg). Both LC-MS and 1H NMR analysis confirmed the formation of a clean product.
Figure 4.22 shows the 1H NMR spectrum for compound 31.
Figure 4.22: 1H NMR spectrum for compound 3-chloro-N -(1,5-dimethyl-1H -imidazol-2-yl)-4-
fluorobenzamide (31)
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The 1H NMR spectrum of compound 31 (Figure 4.22) was very similar to the spectrum
for compound 25 (Figure 4.17, page 45). Both have the hydrogen in the amide (12.00
ppm), the three hydrogens in the phenyl (8.21, 8.11 and 7.41 ppm) and the hydrogen in
the backbone of the imidazole (6.60 ppm). The difference is that compound 31 has a
methyl group instead of a proton at the nitrogen. This is shown with a singlet with three
protons at 3.45 ppm. In addition to this, there are the three hydrogens that represent
the methyl group in the backbone (2.15 ppm) in the upfield region of the spectrum.
Preparation of the PET tracer precursor
To achieve a radiolabelled molecule, the reaction needs to take place in a ”hot cell”. This
is a highly shielded fume hood that protects individuals from radioactivity. Before the
compound was ready for the ”hot-cell”, an HPLC method that separates the precursor
(compound 25) and the radiolabelled product (compound 31 with [11C]CH3), needed to
be made. This was done by making a method and run the precursor and a standard of
compound 31 (without radiolabelling), separately and together. The standard and the
radiolabelled product will have the same retention time with the same method. This can
therefore be used after the radiolabelling reaction, to separate the two compounds and
to see if the reaction worked.
The method that worked well and gave a good separation between the two products, used
the gradient that is shown below (Figure 4.23). The gradient starts with 95 % water and
5 % acetonitrile, and after 5 min it increases to 50 % acetonitrile.
Figure 4.23: Solvent gradient for the separation of the precursor and the standard on HPLC
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The method was first run with the standard without radiolabelling (compound 31) and
the compound got a retention time of 11:32 (left in Figure 4.24). Then the precursor
(compound 25) was run with the same method, and got a retention time of 14:06 min
(right in Figure 4.24). The peak with a retention time of 10:50 in the right chromatogram
(Figure 4.24), is an impurity in the precursor. In the chromatogram of the standard (left
in Figure 4.24), there seems to be a small impurity too that might be the same as for the
precursor, since the retention time is very similar.
Figure 4.24: Chromatogram of the standard and the precursor
To confirm that this method worked after the radiolabelling reaction, where we will see
both of these products, the method was run with a mixture of the two products. The
chromatogram (Figure 4.25) shows a good separation between the products. The first
peak (Region 1) had a retention time of 10:50, that corresponds with the retention time of
the standard (compound 31). The second peak (Region 2) had a retention time of 14:06,
which corresponds to the retention time of the precursor (compound 31). Also here we
can see the peak from the impurity, the first peak that overlaps with the standard.
Figure 4.25: Chromatogram of a mixture of the standard and the precursor
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Compound 31 was prepared in the ”hot lab” using the same procedure as mentioned
above. The only change that was made was the temperature. Instead of using reflux at
60 oC, the reaction was run in RT. This is the temperature that is most used in ”hot
cells”, and was therefore tried in this case too. After the radiolabelling, HPLC was run
with the prepared method and if the radiolabelling worked it would be visible in the
chromatogram that detects the 11C activity. All compounds with 11C activity will give a
peak in this chromatogram.
Figure 4.26 shows the 11C chromatogram of the reaction after the methylation. The big
peak in the chromatogram does not represent the product. It is a very common peak for
the [11C]CH3I, and since this is the only peak in the chromatogram it means that the
reaction did not work. The reason for this might be the change in temperature.
Figure 4.26: Chromatogram for the 11C activity of the product after the methylation of compound 25
For future work with this reaction, a change in temperature would be a good start.
By increasing the temperature, the reaction is more similar to the original procedure.




Most chemicals were purchased commercially and used as received. One exception is
1,3-diiodo-5,5-dimethylhydantoin (DIH) [43], that previously has been synthesized in our
group using continuous flow.
5.2 Experimental description
TLC analyses were performed on silica plates, Camlab Polygram SIL G/UV254. Various
mixtures of hexane/ethyl acetate and dichloromethane/methanol were used as mobile
phases. Solvents were used as received, without any purifications.
Microwave synthesis was carried out on a Biotage Initiator Sixty EXP microwave system.
The temperature scale vary from 40 - 250 oC and the pressure vary from 0 - 20 bar. The
microwave operates at 0 - 400 W at 2.45 GHz. The reactor vials that were used in the
synthesis were 10 mL.
5.3 Spectrometric and spectroscopic descriptions
NMR analysis was performed on a Bruker Biospin AV500, 500 MHz for 1H NMR and a
Bruker 400 MHz. Chemical shifts are given in ppm, coupling constants are given in Hz
and multiplicity are given as singlet (s), doublet (d), doublets of doublets (dd), triplet
(t) and multiplet (m).
LC-MS spectrum were obtained on an Agilent 6420A triple quadrupole mass analyzer
with electrospray ionization (ESI), which is connected to a 1200 series LC module (binary
pump, column compartment/oven, and autosampler). Agilent ZORBAX SB-C18, RRHT;
2.1 × 50 mm × 1.8 µL was used as column. Agilent 1260 Infinity Quaternary LC system
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interfaced to an Agilent 6120 single Quadrupole mass spectrometer. Poroshell 120 EC-
C18; 4.6 mm × 50 mm × 2.7 µL.
GC-MS analysis were performed on a capillary gas chromatograph with a fused silica
column and helium as the carrier gas. The gas chromatograph was connected to a mass
spectrometer using electron ionization (EI) as an ionization source.
Automatic flash column chromatography was carried out on Teledyne CombiFlash Rf
chromatograph, with Agela Flash Column Silica-CS 60 Å.
HPLC analysis for PET tracer percursor were performed on Agilent 1260 infinity with a
radio-HPLC detector Posi-RAM model 4 from LabLogic. The column used was a Luna




Imidazole (1.36 g, 20 mmol), KOH (1.50 g, 26.7 mmol) and acetone (20 mL) were placed
in a round bottle flask with a magnetic stirrer, at 3 oC. Methyl iodide (1.33 mL, 21.4
mmol) was added dropwise to the mixture. The mixture changed color from blank to
white, when methyl iodide was added. After 1.5 h the mixture was extracted with ethyl
acetate and the organic phase was dried over Na2SO4. The solvent was evaporated under
reduced pressure to provide the title compound in a yield of 84 % (1.38 g, 16.7 mmol).
1H NMR (500 MHz, CDCl3): δ = 7.44 (s, 1H), 7.05 (s, 1H), 6.89 (s, 1H), 3.59 (s, 3H)
ppm. Traces of contaminated CDCl3 were observed with a chemical shift at 2.63, 2.18
and 1.26 ppm. MS found 83.1 [M+H+].
1-(1-methyl-1H -imidazol-2-yl)cyclobutan-1-ol (2)
Methyl imidazole (5 mmol, 0.4 mL), was added to a round bottle flask that was flushed
with nitrogen before and after the addition, to avoid moisture. Dry THF (10 mL) was
added to the flask while stirring. The flask was placed in a bath with dry ice and acetone.
When the mixture had cooled down, n-BuLi (5 mmol, 3.125 mL), was added dropwise
to the mixture. After the addition, the reaction stirred for 45 min, before cyclobutanone
(5 mmol, 0.376 mL) was added and the mixture stirred for another 45 min. After the
reaction, the mixture was quenched with H2O (15 mL) and extracted with ethyl acetate.
The organic phase was dried over Na2SO4 and the solvent was evaporated under reduced
pressure to provide the title compound in a yield of 68 % [37]. MS found 153.1 [M+H+].
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4(5)-iodo-1-methyl-1H -imidazole (3)
The desired product was not synthesized
Method 1. Methylimidazole (0.45 mL, 5.7 mmol) and water (50 mL) was added to a 250
mL round bottle flask while stirring and immersed in an ice-water bath. NaOH (50 mL)
was added. In a separate beaker DIH (0.352 g, 1.4 mmol) was weighed in and sulphuric
acid (5 mL) was added dropwise to the beaker. The mixture became a black slurry
and this was added to the flask dropwise in a period of 10 min. Immediately after the
addition, acetic acid (50 % acid and 50 % water) was added until pH 6. The mixture was
saturated with sodium chloride, so a small portion of NaCl was not dissolved. The water
phase was extracted with diethyl ether (3 × 40 mL) and the combined organic phase was
extracted with 10 % HCl (3 × 10 mL). This made the product as a salt that was in the
aqueous phase, so the water was concentrated down. The crude was dissolved in water
(5 mL), and neutralized with a saturated NaHCO3 solution until pH 6. The solution
was saturated with NaCl and extracted with ether (3 × 35 mL). The organic phase was
combined and dried over Na2SO4, filtered and concentrated down under reduced pressure.
1H NMR, LC-MS and GC analysis of the crude product did not show the desired product
[26].
Method 2. To a solution of methylimidazole (0.45 mL, 5.7 mmol) in NaOH (3.9 M, 21
mL), a solution of KI ( 5.12 g, 31 mmol) and I2 (3.04 g, 12.6 mmol) was added dropwise
over a period of 30 min. The reaction mixture was stirred for 23 h in RT, followed by
neutralization with acetic acid, which resulted in precipitation. The mixture was cooled
on ice, filtered with Buchner funnel and washed with cold water and saturated Na2SO4.
Most of the product were dissolved in the washing prosses and 1H NMR and LC-MS
analysis did not show the desired compound [27].
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4(5)-iodoimidazole (4)
Water (50 mL) was added to a round bottle flask and immersed in an ice-bath. Imidazole
(0.390 g, 5.7 mmol) was transferred to the flask, stirred until dissolved and NaOH (3.9
M, 50 mL) was added. In a separate beaker, sulphuric acid (5 mL) was added to DIH
(0.517 g, 1.4 mmol), and vigorously stirred. The resulting viscous mixture was added
dropwise to the imidazole solution over 10min. Immediately following the addition, the
reaction mixture was neutralized until pH 6. The mixture was saturated with sodium
chloride, so a small portion of NaCl was not dissolved. The water phase was extracted
with diethyl ether (3 × 40 mL). The combined organic phase was extracted with 10%
HCl (3 × 10 mL), and the product became a salt. The aqueous phase was combined and
the water was evaporated. The crude was dissolved in water (5 mL), and neutralized
with a saturated NaHCO3 solution until pH 6. The solution was saturated with NaCl
and extracted with ether (3 × 35 mL). The organic phase was combined and dried over
Na2SO4, filtered and evaporated under reduced pressure to provide the title compound
in a yield of 49 % (0.133 g, 0.69 mmol) [26]. 1H NMR (500 MHz, CDCl3): δ = 9.12 (s,
1H), 7.81 (s, 1H) ppm. MS found 195.0 [M+H+].
4-cyclobutyl-1H -imidazole (5)
The desired product was not synthesized
Method 1. 4-(5)-iodo-1H -imidazole (68 mg, 0.34 mmol), cyclobutylboronic acid (1.5
equiv), TBAB (0.008 g, 0.025 mmol) K2HPO4 (0,65 mmol) and Pd(PPh3)4 (3 mol %),
were transferred to a microwave reactor tube equipped with a magnetic stirring bar. The
tube was sealed and carefully flushed with argon. Methanol/water (4:1)(5 mL) was added
to the tube and the tube was placed in the microwave cavity and heated at 100 oC for 60
min. After the reaction time, the crude reaction mixture was dissolved in HCl (10 %, 20
mL) and stirred vigorously. Not all the solid dissolved in the HCl. The aqueous phase
was washed with diethyl ether (20 mL) to remove the boroxxine and PPh3. NaOH was
added to the aqueous phase until pH 12, and the solution became white and milky. The
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alkaline solution was then extracted with diethyl ether (3 × 20 mL), organic extracts
were combined and dried over anhydrous Na2SO4. The drying agent was removed and
the solvent was evaporated under reduced pressure. LC-MS and 1H NMR analysis of the
product was collected, but the desired product was not observed [38].
Method 2. 4-(5)-iodo-1H -imidazole (68 mg, 0.34 mmol), cyclobutylboronic acid (0,41
mmol, 41 mg), K2CO3 ( 1.02 mmol, 141 mg) was added to a microwave tube, dissolved
in toluene/water (2 mL/0.6 mL) and protected in an atmosphere of nitrogen. Pd(PPh3)4
(3 mg) was dissolved in toluene (0.5 mL) and added to the reaction tube. The reaction
stirred at 90 oC in a microwave for 1 h. After the reaction, the solvent was evaporated
under reduced pressure. The crude mixture was dissolved in water and extracted with
DCM (3 × 20 mL). The organic phases were combined and dried over Na2SO4. The
drying agent was removed and the solvent was evaporated under reduced pressure. LC-
MS and 1H NMR analysis of the product was collected, but the desired product was not
observed [39].
N -Tosyl-4-iodoimidazole (6)
4(5)-iodoimidazole (5.00 g, 25.8 mmol) and TosCl (4.91 g, 25.8 mmol) where transferred
to a round bottle flask (100 mL) and flushed with argon gas. Dry THF (40 mL) was
added and stirred to dissolve the solid. Et3N was added the mixture stirred for 4 h in RT.
After the reaction, the mixture was filtrated, and the solvent evaporated under reduced
pressure. Yellow/white precipitate formed and the crude product was re-crystallized with
DCM to provide the title compound as white crystals in a yield of 42 % [27]. 1H NMR




The desired product was not synthesized
4-iodo-1-tosyl-1H -imidazole (0.57 mmol, 198 mg), was added to a microwave tube and
flushed with argon. Dry THF (2 mL) was added to the tube while stirring. The tube
was placed in a bath with dry ice and acetone, and nBuLi (1.15 mmol, 0.46 mL) was
added dropwise to the mixture. After the addition, the reaction stirred for 45 min before
cyclobutanone (0.86 mmol, 65 µL) was added and the mixture stirred for 1 h. After the
reaction, the mixture was quenched with H2O (15 mL) and extracted with ethyl acetate
(3 × 20 mL). The organic phase was combined, dried over Na2SO4 and the solvent was
evaporated under reduced pressure. 1H NMR and LC-MS analysis of the product was
collected, but the desired molecule was not observed [37].
1-(2-amino-1H -imidazol-5-yl)ethan-1-ol (8)
2-aminoimidazole (1 mmol, 83 mg) was weighted in a vial and dissolved in H2O (5 mL).
Na2CO3 (0.6 mmol, 63 mg) was added and stirred for 10 min. After 10 min acetaldehyde
(1.2 mmol, 68 µL) was added and stirred over night. After 19 h LC-MS was checked and
showed starting material and a small peak of product. Automated flash chromatography
was used to separate the product, but the desired product was not able to be isolated
[34]. MS found 128.1 [M+H+].
1-methyl-2-nitro-1H -imidazole (9)
2-nitroimidazole (1.76 mmol, 200 mg) and Cs2CO3 (2.64 mmol, 860 mg, 1.5 equiv) were
dissolved in MeCN (15 mL) and CH3I (2.11 mmol, 131 µL, 1.2 equiv) was added dropwise
at 0 oC. After the addition the reaction mixture stirred for 1 h at 65 oC with reflux.
After 1 h the reaction was quenched with water and concentrated down under reduced
pressure. The resulting residue was diluted in water and extracted with ethyl acetate
and the combined organic layers were dried over Na2SO4 and concentrated down under
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reduced pressure. The product was purified with silica gel column chromatography with a
mixture of hexane/ethyl acetate (100:0 % - 40:60 % gradient) to give the title compound
as a white solid in a yield of 68% (152 mg) [32]. 1H NMR (400 MHz, CDCl3): δ = 7.14
(s, 1H), 7.05 (s, 1H), 4.07 (s, 3H). MS found 128.1 [M+H+].
1-methyl-1H -imidazol-2-amine (10)
Compound 9 (0.37 mmol, 47 mg) and Pd(OH)2 (0.063 mmol, 9 mg) was added to a round
bottle flask and dissolved in EtOH (15 mL). The flask was capped and flushed with argon
gas. A balloon with H2 gas was added and the reaction stirred overnight in RT. After
the reaction the mixture was filtrated with celite and the solvent was concentrated down
under reduced pressure, to give the title compound in a yield of 63 % (61mg) [41]. 1H
NMR (400 MHz, DMSO): δ = 6.48 (s, 1H), 6.29 (s, 1H), 5.17 (s, 2H), 3.29 (s, 3H). MS
found 98.1 [M+H+].
1-(2-amino-1-methyl-1H -imidazol-5-yl)ethan-1-ol (11)
1-methyl-1H -imidazole-2-amine (1 mmol, 97 mg) was weighted in a vial and dissolved in
H2O (5 mL). Na2CO3 (1.8 mmol, 189 mg) was added and stirred for 10 min. After 10
min acetaldehyde (3.6 mmol, 0.2 mL) was added and stirred for 24 h, to give a crude
mixture containing product, with some impurities. After the reaction, the solvent was
evaporated under reduced pressure, and the product was dissolved in methanol to filter
off undissolved salt. Methanol was evaporated under reduced pressure and the crude
product was dried [34]. MS found 142.1[M+H+].
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1-(2-amino-1-methyl-1H -imidazol-5-yl)-2-methylpropan-1-ol (12)
1-methyl-1H -imidazole-2-amine (1 mmol, 97 mg) was weighted in a vial and dissolved
in H2O (5 mL). Na2CO3 (1.8 mmol, 189 mg) was added and stirred for 10 min. After
10 min isobutyraldehyde (3.6 mmol, 0.328 mL) was added and stirred for 24 h, to give
a crude mixture containing product, with some impurities and starting material. After
the reaction the solvent was evaporated under reduced pressure, and the product was
dissolved in methanol to filter off undissolved salt. Methanol was evaporated under
reduced pressure and the crude product was dried [34]. MS found 170.1 [M+H+].
1-(2-amino-1-methyl-1H -imidazol-5-yl)cyclobutan-1-ol (13)
1-methyl-1H -imidazole-2-amine (1 mmol, 97 mg) was weighted in a vial and dissolved
in H2O (5 mL). Na2CO3 (1.8 mmol, 189 mg) was added and stirred for 10 min. After
10 min cyclobutanone (3.6 mmol, 0.27 mL) was added and stirred for 48 h at 40 oC,
to give a crude mixture containing product, with some impurities and starting material.
After the reaction the solvent was evaporated under reduced pressure, and the product
was dissolved in methanol to filter off undissolved salt. Methanol was evaporated under
reduced pressure and the crude product was dried [34]. MS found 168.2 [M+H+].
3-chloro-4-fluoro-N -(5-(1-hydroxyethyl)-1-methyl-1H -imidazol-
2-yl) benzamide (14)
Crude solid from the synthesis of compound 11 (90 mg) was dissolved in DCM (10 mL).
TEA (4 mmol, 0.56 mL) and 3-chloro-4-fluoro benzoyl chloride (1 mmol, 193 mg) was
added and the reaction stirred in RT for 30 min to give a crude mixture containing
product. After the reaction time the reaction was quenched with sodium bicarbonate (15
mL) and extracted with DCM (3 × 20 mL). The organic phase was combined, washed
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with saturated NaCl solution, dried over anhydrous MgSO4 and concentrated down under
reduced pressure. The crude mixture was purified with silica gel column chromatography
with a mixture of DCM/MeOH (100:0 % - 90:10 % gradient). The product was crystalized
and completely purified with DCM to give the title compound as white crystals in a overall
yield of 6 % (18 mg) [3]. 1H NMR (400 MHz, DMSO): δ = 12.12 (s, 1H), 8.23 (dd, J=7.8,
2, 1H), 8.12 (m, 1H), 7.42 (t, J=8.8, 1H), 6.68 (s, 1H), 5.29 (d, J=5.9, 1H), 4.73 (m, 1H),
3.57 (s, 3H), 1.42 (d, J=6.4, 3H). MS found 298.1 [M+H+].
3-chloro-4-fluoro-N -(1-methyl-5-vinyl-1H -imidazol-2-yl)
benzamide (15)
The crude solid from the synthesis of compound 11 (0,300 g) was dissolved in 1,2-
dichloroethane (10 mL), TEA (4 mmol, 0.56 mL) and 3-chloro-4-fluoro benzoyl chloride
(2.2 mmol, 424 mg) was added and stirred over night at 70 oC, to give a crude mix-
ture containing product. After the reaction time the reaction was quenched with sodium
bicarbonate (15 mL) and extracted with DCM (3 × 20 mL). The organic phase was
combined, washed with saturated NaCl solution, dried over anhydrous MgSO4 and con-
centrated down under reduced pressure. The crude mixture was purified with silica gel
column chromatography with a mixture of hexane/ethyl acetate (100:0 % - 50:50 %) to
give the title compound as a white solid in a overall yield of 9 % (25 mg) [3]. 1H NMR
(400 MHz, DMSO): δ = 12.33 (s, 1H), 8.23 (d, J=7.3, 1H), 8.13 (m, 1H), 7.42 (t, J=8.8x2,
1H), 7.11 (s, 1H), 6.61 (dd, J=17.6,11.7, 1H) 5.77 (d, J=17.6, 1H), 5.32 (d, J=11.2, 1H),




Crude solid from the synthesis of compound 12 (230 mg) was dissolved in DCM (10
mL). TEA (4 mmol, 0.56 mL) and 3-chloro-4-fluoro benzoyl chloride (1 mmol, 193 mg)
was added and the reaction stirred in RT for 30 min to give a crude mixture containing
product. After the reaction time the reaction was quenched with sodium bicarbonate (15
mL) and extracted with DCM (3 × 20 mL). The organic phase was combined, washed
with saturated NaCl solution, dried over anhydrous MgSO4 and concentrated down under
reduced pressure. The crude mixture was purified with silica gel column chromatography
with a mixture of DCM/MeOH (100:0 % - 90:10 % gradient). The product was crystalized
with a mixture of hexane/ethyl acetate to get it completely pure and to give the title
compound as white crystals in a overall yield of 5 % (14 mg) [3]. 1H NMR (400 MHz,
DMSO): δ = 12.13 (s, 1H), 8.22 (dd, J=7.6, 1.7, 1H), 8.13 (m, 1H), 7.42 (t, J=8.8, 1H),
6.67 (s, 1H), 5.33 (d, J=5.4, 1H), 4.20 (dd, J=7.3, 5.9, 1H), 3.56 (s, 3H), 1.98 (m, 1H),
0.97 (d, 3H, J=6.4), 0.81 (d, 6.4, 3H). MS found 326.1 [M+H+].
3-chloro-4-fluoro-N -(5-(1-hydroxycyclobutyl)-1-methyl-1H -
imidazol-2-yl)benzamide (17)
Crude solid from the synthesis of compound 13 (0.307 g) was dissolved in DCM (10
mL). TEA (4 mmol, 0.56 mL) and 3-chloro-4-fluoro benzoyl chloride (1 mmol, 193 mg)
was added and the reaction stirred for 1 h in RT, to give a crude mixture containing
product. After the reaction time the reaction was quenched with sodium bicarbonate (15
mL) and extracted with DCM (3 × 20 mL). The organic phase was combined, washed
with saturated NaCl solution, dried over anhydrous MgSO4 and concentrated down under
reduced pressure. The crude mixture was purified with silica gel column chromatography
with a mixture of DCM/MeOH (100:0 % - 90:10 % gradient). The product was completely
purified with crystallization with a mixture of hexane/ethyl acetate to give the title
compound as white crystals in a overall yield of 11 % (36 mg) [3]. 1H NMR (400 MHz,
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DMSO): δ = 12.11 (s, 1H), 8.23 (dd, J=7.6, 1.17, 1H), 8.12 (m, 1H), 7.42 (t, J=8.8, 1H),
6.84 (s, 1H), 5.79 (s, 1H), 3.53 (s, 3H), 2.41 (m, 2H), 2.25 (m, 2H), 1.74 (m, 1H), 1.49
(m, 1H). MS found 324.1 [M+H+].
3-chloro-4-fluoro-N -(1H -imidazol-2-yl)benzamide (18)
1-methylimidazole-2-amin (1 mmol, 97 mg) was dissolved in DCM (10 mL). TEA (4
mmol, 0.56 mL) and 3-chloro-4 fluoro benzoyl chloride (1 mmol, 193 mg) was added and
the reaction stirred in RT for 30 min to give a crude mixture containing product. After the
reaction time the reaction was quenched with sodium bicarbonate (15 mL) and extracted
with DCM (3 × 20 mL). The organic phase was combined, washed with saturated NaCl
solution, dried over anhydrous MgSO4 and concentrated down under reduced pressure.
The product was purified with crystallization with ethyl ether to give the title compound
as white crystals in a overall yield of 38 % (96 mg) [3]. 1H NMR (400 MHz, DMSO):
δ = 12.19 (s,1H), 8.22 (dd, J=7.8,2, 1H), 8.10 (m, 1H), 7.43 (t, J=8.8x2, 1H), 7.01 (d,
J=1.5x2, 1H), 6.82 (d, J=2.4, 1H), 3.52 (s, 3H). MS found 254.0 [M+H+].
N -(5-(1-hydroxyethyl)-1-methyl-1H -imidazol-2-yl)benzamide (19)
Crude mixture of compound 11 (222 mg) was dissolved in DCM (10 mL). TEA (4 mmol,
0.56 mL) and benzoyl chloride (1 mmol, 116 µL) was added and the reaction stirred for
30 min in RT, to give a crude mixture containing product. After the reaction time the
reaction was quenched with sodium bicarbonate (15 mL) and extracted with DCM (3 × 20
mL). The organic phase was combined, washed with saturated NaCl solution, dried over
anhydrous MgSO4 and concentrated down under reduced pressure. The crude mixture
was purified with silica gel column chromatography with a mixture of DCM/MeOH (100:0
% - 90:10 % gradient). The product was completely purified by crystallization with DCM
to give the title compound as white crystals in a overall yield of 5 % (11 mg) [3]. 1H
NMR (400 MHz, DMSO): δ = 12.12 (s, 1H), 8.12 (s, 2H), 7.40 (s, 3H), 6.67 (s, 1H), 5.24
(s, 1H), 4.71 (m, 1H), 3.53 (s, 3H), 1.41 (d, J=6.4, 3H). MS found 246.1 [M+H+].
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N -(1-methyl-5-vinyl-H -imidazol-2-yl)benzamide (20)
Crude product of compound 11 (222 mg) was dissolved in 1,2-dichloroethane (10 mL).
TEA (4 mmol, 0.56 mL) and benzoyl chloride (2.2 mmol, 0.25 mL) was added and stirred
over night at 70 oC, to give a crude mixture containing product. After the reaction
time the reaction was quenched with sodium bicarbonate (15 mL) and extracted with
DCM (3 × 20 mL). The organic phase was combined, washed with saturated NaCl
solution, dried over anhydrous MgSO4 and concentrated down under reduced pressure.
The crude mixture was purified with silica gel column chromatography with a mixture
of DCM/MeOH (100:0 % - 90:10 % gradient). The product was not completely pure [3].
MS found 228.1 [M+H+].
N -(5-(1-hydroxy-2-methylpropyl)-1-methyl-1H -imidazol-2-yl)
benzamide (21)
The crude mixture of compound 12 (275 mg) was dissolved in DCM (10 mL). TEA (4
mmol, 0.56 mL) and benzoyl chloride (1 mmol, 116 µL) was added and the reaction
stirred for 30 min at RT, to give a crude mixture containing product. After the reaction
time, the reaction was quenched with sodium bicarbonate (15 mL) and extracted with
DCM (3 × 20 mL). The organic phase was combined, washed with a saturated NaCl
solution, dried over anhydrous MgSO4 and concentrated down under reduced pressure.
The crude mixture was purified with silica gel column chromatography with a mixture
of DCM/MeOH (100:0 % - 90:10 % gradient). The product was completely purified by
crystallization with ethyl ether to give the title compound as white crystals in an overall
yield of 3 % (9 mg) [3]. 1H NMR (400 MHz, DMSO): δ = 12.14 (s, 1H), 8.15 (d, J=6.4,
2H), 7.39 (d, J=7.3, 3H), 6.65 (s, 1H), 5.32 (s, 1H), 4.19 (t, J=6.6x2, 1H), 3.56 (s, 3H),




Crude solid from the synthesis of compound 13 (0.243 g) was dissolved in DCM (10 mL).
TEA (4 mmol, 0.56 mL) and benzoyl chloride (1 mmol, 116 µL) was added and the
reaction stirred for 30 min at RT, to give a crude mixture containing product. After the
reaction time the reaction was quenched with sodium bicarbonate (15 mL) and extracted
with DCM (3 × 20 mL). The organic phase was combined, washed with a saturated NaCl
solution, dried over anhydrous MgSO4 and concentrated down under reduced pressure.
The crude mixture was purified with silica gel column chromatography with a mixture
of DCM/MeOH (100:0 % - 90:10 % gradient). The product was completely purified by
crystallization with DCM to give the title compound as white crystals in a overall yield
of 3 % (8 mg) [3]. 1H NMR (400 MHz, DMSO): δ = 12.14 (s, 1H) 8.14 (s, 2H), 7.40 (s,
3H), 6.82 (s, 1H), 5.77 (s, 1H), 3.53 (s, 3H), 2.41 (m, 2H), 2.25 (m, 2H), 1.74 (m, 1H)
1.51 (m, 1H). MS found 272.1 [M+H+].
N -(1-methyl-1H -imidazol-2-yl)benzamide (23)
1-methylimidazole-2-amin (1 mmol, 97 mg) was dissolved in DCM (10 mL). TEA (4 mmol,
0.56 mL) and benzoyl chloride (1mmol, 116µL) was added and the reaction stirred for
30 min at RT, to give a crude mixture containing product. After the reaction time the
reaction was quenched with sodium bicarbonate (15 mL) and extracted with DCM (3 × 20
mL). The organic phase was combined, washed with saturated NaCl solution, dried over
anhydrous MgSO4 and concentrated down under reduced pressure. The crude mixture
was purified with silica gel column chromatography with a mixture of DCM/MeOH (100:0
% - 90:10 % gradient). The product was completely purified by crystallization with ethyl
ether to give the title compound as white crystals in a overall yield of 17 % (33 mg) [3].
1H NMR (400 MHz, DMSO): δ = 12.21 (s, 1H) 8.10 (s, 2H), 7.42 (s, 3H), 7.01 (s, 1H)
6.80 (s, 1H), 3.49 (s, 3H). MS found 202.1 [M+H+].
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3-chloro-4-fluoro-N -(1H -imidazol-2-yl)benzamide (24)
2-aminoimidazole (1.08 mmol, 90 mg) was dissolved in DCM (10 mL). TEA (4 mmol,
0.56 mL) and 3-chloro-4-fluoro benzoyl chloride (1 mmol, 193 mg) was added and the
reaction stirred for 30 min at RT, to give a crude mixture containing product. After
extracting with DCM, the water phase still contained the product, due to low solubility
of the product in DCM. The water phase was therefor extracted with ethyl ether and
concentrated down. The crude solid of the DCM layer were dissolved in ethyl acetate and
the solid was filtrated off. The ethyl acetate layer was dried over Na2SO4 and concentrated
down to give the title compound in a overall yield of 36 % (86 mg) [3]. 1H NMR (400
MHz, DMSO): δ = 7.98 (dd, J=6.8,2, 1H), 7.76 (m, 1H), 7.59 (t, J=8.8x2, 1H), 6.75 (s,
2H), 6.69 (d, J=2, 1H), 6.47 (d, J=2, 1H). MS found 240.1 [M+H+].
3-chloro-4-fluoro-N -(5-methyl-1H -imidazol-2-yl)benzamide (25)
5-methylimidazole-2-amine (1,02 mmol, 99 mg) was dissolved in DCM (10 mL). TEA
(4 mmol, 0.56mL) and 3-chloro-4-fluoro benzoyl chloride (1 mmol, 193 mg) was added
and the reaction stirred for 30 min at RT, to give a crude mixture containing product.
After the reaction time the reaction was quenched with sodium bicarbonate (15 mL)
and extracted with DCM (3 × 20 mL). The organic phase was combined, washed with
saturated NaCl solution, dried over anhydrous MgSO4 and concentrated down under
reduced pressure. The crude mixture was purified with silica gel column chromatography
with a mixture of hexane/ethyl acetate (100:0 % - 50:50 % gradient). The product was
completely purified by crystallization with ethyl ether to give the title compound as white
crystals in a overall yield of 8 % (19 mg) [3]. 1H NMR (400 MHz, DMSO): δ = 11.77 (s,
2H) 8.19 (dd, J=7.3,2, 1H), 8.03 (m, 1H), 7.45 (t, J=9x2, 1H), 6.52 (s, 1H), 2.09 (s, 3H).
MS found 254.0 [M+H+].
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N -(1H -imidazol-2-yl)benzamide (26)
1H -imidazole-2-amine (1 mmol, 83 mg) was dissolved in DCM (10 mL). TEA (4 mmol,
0.56 mL) and benzoyl chloride (1mmol, 116 µL) was added and the reaction stirred for
30 min at RT, to give a crude mixture containing product. After the reaction time the
reaction was quenched with sodium bicarbonate (15 mL) and extracted with DCM (3 ×
20 mL). The organic phase was combined, washed with saturated NaCl solution, dried
over anhydrous MgSO4 and concentrated down under reduced pressure. The product was
purified with silica gel column chromatography with a mixture of hexane/ethyl acetate
(100:0 % - 50:50 % gradient), to give the title compound as white crystals in a overall
yield of 6 % (11 mg) [3]. 1H NMR (400 MHz, CDCl3): δ = 8.03 (m, 2H), 7.60 (m, 1H),
7.51 (m, 2H), 6.65 (s, 2H). MS found 188.1 [M+H+].
N -(5-methyl-1H -imidazol-2-yl)benzamide (27)
5-methylimidazole-2-amine (1 mmol, 97 mg) was dissolved in DCM (10 mL). TEA (4
mmol, 0.56 mL) and benzoyl chloride (1 mmol, 116µL) was added and the reaction
stirred for 30 min at RT, to give a crude mixture containing product. After the reaction
time the reaction was quenched with sodium bicarbonate (15 mL) and extracted with
DCM (3 × 20 mL). The organic phase was combined, washed with saturated NaCl
solution, dried over anhydrous MgSO4 and concentrated down under reduced pressure.
The crude mixture was purified with silica gel column chromatography with a mixture of
hexane/ethyl acetate (100:0 % - 40:60 % gradient), to give the title compound as white
crystals in a overall yield of 12 % (23 mg) [3]. 1H NMR (400 MHz, MeOH): δ = 7.97 (m,
2H), 7.56 (m, 1H), 7.49 (m, 2H), 6.56 (s, 1H), 2.19 (s, 3H). MS found 202.1 [M+H+].
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1-benzyl-2-nitro-1H -imidazole (28)
2-nitroimidazole (0.5 mmol, 57 mg) and Cs2CO3 (0.75 mmol, 244 mg, 1.5 equiv) was
dissolved in MeCN (3 mL) and benzyl bromide (0.6 mmol, 71 µL, 1.5 equiv) was added
dropwise at 0 oC. The reaction mixture stirred for 1 h with reflux at 65 oC. After 1 h the
reaction was quenched with water and concentrated down under reduced pressure. The
resulting residue was diluted in water and extracted with ethyl acetate. The combined
organic layers were dried over Na2SO4 and concentrated down under reduced pressure.
The product was purified with silica gel column chromatography with a mixture of hex-
ane/ethyl acetate (100:0 % - 60:40 % gradient) to give the title compound as a yellow
solid in a overall yield of 43 % (88 mg) [32]. 1H NMR (400 MHz, CDCl3): δ = 7.38 (m,
3H), 7.21 (m, 2H), 7.17 (s, 1H), 7.05 (s, 1H), 5.60 (s 2H). MS found 204.1 [M+H+].
1-benzyl-1H -imidazol-2-amine (29)
Compound 28 (0.23 mmol, 47 mg) was dissolved in 5 mL of ethanol:water (9:1), iron
powder (5 equiv, 1.15 mmol, 65 mg) and acetic acid (10 drops) was added and the
reaction stirred at 70 oC under reflux over the weekend. After 3 days LC-MS confirmed
conversion and the mixture was filtrated with celite and concentrated down. MS found
174.1 [M+H+].
1-(2-amino-1-benzyl-1H -imidazol-5-yl)ethan-1-ol (30)
The desired product was not synthesized
Crude mixture of compound 29 (153 mg, 0.88 mmol) was dissolved in H2O (5 mL).
Na2CO3 (1.8 mmol, 189 mg) was added and stirred for 10 min. After 10 min acetaldehyde
(3.6 mmol, 0.2 mL) was added and stirred for 24 h in RT. After the reaction, the solvent
was evaporated under reduced pressure, and the product was dissolved in methanol to
filter off undissolved salt. Methanol was evaporated under reduced pressure and the crude
product was dried [34]. LC-MS was collected but the desired product was not observed.
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3-chloro-N -(1,5-dimethyl-1H -imidazol-2-yl)-4-fluorobenzamide (31)
Compound 25 (0.46 mmol, 117 mg) and Cs2CO3 (1.5 equiv, 0.69 mmol, 225 mg) was
dissolved in MeCN (15 mL) and CH3I (1.2 equiv, 0.55 mmol, 34 µL) was added dropwise
at 0 oC. The reaction mixture stirred for 1 h with reflux at 65 oC. After 1h the reaction
was quenched with water and concentrated down under reduced pressure. The result-
ing residue was diluted in water and extracted with ethyl acetate. The combined organic
layers were dried over Na2SO4 and concentrated down under reduced pressure. The prod-
uct was purified with silica gel column chromatography with a mixture of hexane/ethyl
acetate (100:0 % - 40:60 % gradient) and crystallized with ethyl ether to give the title
compound as white crystals in a overall yield of 18 % (23 mg) [32]. 1H NMR (400 MHz,
DMSO): δ = 12.00 (s, 1H), 8.22 (dd, J=7.4,2, 1H), 8.11 (m, 1H), 7.41 (t, J=8.8x2, 1H),
6.60 (s, 1H), 3.46 (s, 3H), 2.15 (s, 3H). MS found 268.0 [M+H+].
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Appendix B Spectral data
Proton spectrum of 1-methyl-1H -imidazole (1)
80
LC-MS spectrum of of 1-methyl-1H -imidazole (1)
81
LC-MS spectrum of 1-(1-methyl-1H -imidazol-2-yl)cyclobutan-1-ol (2)
82
Proton spectrum of 4(5)-iodoimidazole (4)
83
LC-MS spectrum of 4(5)-iodoimidazole (4)
84
Proton spectrum of N -Tosyl-4-iodoimidazole (6)
85
LC-MS spectrum of 1-(2-amino-1H -imidazol-5-yl)ethan-1-ol (8)
86
Proton spectrum of 1-methyl-2-nitro-1H -imidazole (9)
87
LC-MS of 1-methyl-2-nitro-1H -imidazole (9)
88
Proton spectrum of 1-methyl-1H -imidazol-2-amine (10)
89
LC-MS spectrum of 1-methyl-1H -imidazol-2-amine (10)
90
LC-MS spectrum of 1-(2-amino-1-methyl-1H -imidazol-5-yl)ethan-1-ol (11)
91
LC-MS spectrum of 1-(2-amino-1-methyl-1H -imidazol-5-yl)-2-methylpropan-
1-ol (12)
92
LC-MS spectrum of 1-(2-amino-1-methyl-1H -imidazol-5-yl)cyclobutan-1-ol (13)
93
Proton spectrum of 3-chloro-4-fluoro-N -(5-(1-hydroxyethyl)-1-methyl-1H -imidazol-
2-yl) benzamide (14) (380-28)
94
LC-MS spectrum of 3-chloro-4-fluoro-N -(5-(1-hydroxyethyl)-1-methyl-1H -imidazol-
2-yl) benzamide (14)
95
Proton spectrum of 3-chloro-4-fluoro-N -(1-methyl-5-vinyl-1H -imidazol-2-yl)
benzamide (15)
96
LC-MS spectrum of 3-chloro-4-fluoro-N -(1-methyl-5-vinyl-1H -imidazol-2-yl)
benzamide (15)
97
Proton spectrum of 3-chloro-4-fluoro-N -(5-(1-hydroxy-2-methylpropyl)-1-methyl-
1H -imidazol-2-yl) benzamide (16)
98
LC-MS spectrum of 3-chloro-4-fluoro-N -(5-(1-hydroxy-2-methylpropyl)-1-methyl-
1H -imidazol-2-yl) benzamide (16)
99
Proton spectrum of 3-chloro-4-fluoro-N -(5-(1-hydroxycyclobutyl)-1-methyl-
1H -imidazol-2-yl) benzamide (17)
100
LC-MS spectrum of 3-chloro-4-fluoro-N -(5-(1-hydroxycyclobutyl)-1-methyl-
1H -imidazol-2-yl) benzamide (17)
101
Proton spectrum of 3-chloro-4-fluoro-N -(1H -imidazol-2-yl)benzamide (18)
102
LC-MS spectrum of 3-chloro-4-fluoro-N -(1H -imidazol-2-yl)benzamide (18)
103
Proton spectrum of N -(5-(1-hydroxyethyl)-1-methyl-1H -imidazol-2-yl)
benzamide (19)
104
LC-MS spectrum of N -(5-(1-hydroxyethyl)-1-methyl-1H -imidazol-2-yl)
benzamide (19)
105
LC-MS spectrum of N -(1-methyl-5-vinyl-H -imidazol-2-yl)benzamide (20)
106
Proton spectrum of N -(5-(1-hydroxy-2-methylpropyl)-1-methyl-1H -imidazol-
2-yl)benzamide (21)
107
LC-MS spectrum of N -(5-(1-hydroxy-2-methylpropyl)-1-methyl-1H -imidazol-
2-yl)benzamide (21)
108
Proton spectrum of N -(5-(1-hydroxycyclobutyl)-1-methyl-1H -imidazol-2-yl)
benzamide (22)
109
LC-MS spectrum of N -(5-(1-hydroxycyclobutyl)-1-methyl-1H -imidazol-2-yl)
benzamide (22)
110
Proton spectrum of N -(1-methyl-1H -imidazol-2-yl)benzamide (23)
111
LC-MS spectrum of N -(1-methyl-1H -imidazol-2-yl)benzamide (23)
112
Proton spectrum of 3-chloro-4-fluoro-N -(1H -imidazol-2-yl)benzamide (24)
113
LC-MS spectrum of 3-chloro-4-fluoro-N -(1H -imidazol-2-yl)benzamide (24)
114
Proton spectrum of 3-chloro-4-fluoro-N -(5-methyl-1H -imidazol-2-yl)
benzamide (25)
115
LC-MS spectrum of 3-chloro-4-fluoro-N -(5-methyl-1H -imidazol-2-yl)
benzamide (25)
116
Proton spectrum of N -(1H -imidazol-2-yl)benzamide (26)
117
LC-MS spectrum of N -(1H -imidazol-2-yl)benzamide (26)
118
Proton spectrum of N -(5-methyl-1H -imidazol-2-yl)benzamide (27)
119
LC-MS spectrum of N -(5-methyl-1H -imidazol-2-yl)benzamide (27)
120
Proton spectrum of 1-benzyl-2-nitro-1H -imidazole (28)
121
LC-MS spectrum of 1-benzyl-2-nitro-1H -imidazole (28)
122
LC-MS spectrum of 1-benzyl-1H -imidazol-2-amine (29)
123
Proton spectrum of 3-chloro-N -(1,5-dimethyl-1H -imidazol-2-yl)-4-fluoro
benzamide (31)
124
LC-MS spectrum of 3-chloro-N -(1,5-dimethyl-1H -imidazol-2-yl)-4-fluoro
benzamide (31)
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